STOCK TITAN

Palomino Laboratories' 9-month loss widens to $7.03M

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
10-Q

Rhea-AI Filing Summary

Palomino Laboratories Inc. (PALX) reported no revenue for the nine months ended September 30, 2026, and a net loss of $7.028 million, versus $2.422 million a year earlier. Third-quarter net loss was $4.420 million. Nine-month research and development expense was $2.910 million, and general and administrative expense was $4.120 million.

At September 30, 2026, cash and equivalents were $17.788 million, while nine-month operating cash outflow was $3.811 million. Management expects existing cash to support operations for at least one year from issuance. An April private placement generated $17.0 million in gross proceeds and $14.8 million in net proceeds after $2.154 million of issuance costs.

PALX completed its acquisition of Vega Links on July 31, 2026, issuing 4,472,000 restricted shares with a fair value of $16.9 million. The acquisition added Vega Links’ high-speed interconnect integrated circuit and digital signal processing technology, as well as its engineering team. $29,000 was included in consideration transferred for pre-combination service; the remaining award value relates to post-combination service and is recognized as stock-based compensation over the vesting period.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 2 points

How the balance works

Positive

  • None.

Negative

  • Moderate pointNine-month net loss was $7.028 million, versus $2.422 million in 2025.
  • Moderate pointNine-month operating cash use was $3.811 million, versus $391,000 in 2025.

Filing Explained

The amendment changes future plan-share capacity, but does not itself report an issuance of shares.

The Form 10-Q reports that stockholders approved an amendment to the 2025 Equity Incentive Plan at the November 5, 2026 annual meeting. The share reserve is set at all times to the greater of 10,000,000 shares or 15% of issued and outstanding common shares on an as-converted basis, and increases under that formula require no further plan amendment. This changes future plan-share capacity; it does not report that the amendment itself issued shares.

At September 30, 2026, 4,360,000 of the 4,472,000 Vega Links consideration shares were unvested and subject to repurchase at the original purchase price if service ended before vesting. Associated purchase-price deposits were recorded as $18 thousand in current and $38 thousand in noncurrent liabilities; as shares vest, the related liability is reclassified to common stock and additional paid-in capital.

Revenue $0 Nine months ended September 30, 2026; the company also reported no revenue for the comparable 2025 period.
Net loss $7.028 million loss Nine months ended September 30, 2026; $2.422 million loss for the comparable 2025 period.
Net cash used in operating activities $3.811 million Nine months ended September 30, 2026; $391,000 for the comparable 2025 period.
Cash and cash equivalents $17.788 million As of September 30, 2026.
Private placement gross proceeds $17.0 million April 2026 private placement and additional closing.
Shares issued in Vega Links acquisition 4,472,000 shares Restricted common shares issued at the July 31, 2026 acquisition closing.
Fair value of Vega Links consideration shares $16.9 million Acquisition-date fair value of the consideration shares.
Unrecognized stock-based compensation cost $17.4 million As of September 30, 2026; expected recognition over a weighted-average period of 3.4 years.
fabless semiconductor company technical
"The Company is a fabless semiconductor company"
A fabless semiconductor company designs and develops computer chips and related circuitry but does not own or operate the factories that manufacture them; instead it outsources production to third‑party foundries. Like an architect who creates plans and hires a contractor to build the house, a fabless firm focuses on design, intellectual property and product roadmaps while relying on partners for fabrication, which affects capital needs, profit margins and supply‑chain exposure—factors investors watch.
microLED-based optoelectronic solutions technical
"high-performance microLED-based optoelectronic solutions for data communication"
gallium nitride (GaN) technical
"advanced gallium nitride (GaN) compound semiconductor materials"
Gallium nitride (GaN) is a durable semiconductor material used to build electronic components that switch power and radio signals faster and with less energy loss than older silicon parts. Think of it as a more efficient, high-performance engine that lets devices be smaller, run cooler, and handle higher voltages; investors watch GaN adoption because it can lower manufacturing and operating costs, enable new products, and shift competitive advantage and profit margins across chipmakers and equipment makers.
optical interconnects technical
"ultra-high-speed, energy-efficient optical interconnects"
Optical interconnects are systems that use light instead of electrical signals to move data between parts of computers, data centers, or telecom equipment, like replacing copper wires with tiny light pipes. They matter to investors because they can greatly increase speed and capacity while lowering power use and heat, making digital networks faster and cheaper to scale; think of swapping a crowded city road for a high-speed rail line that carries much more traffic efficiently.
in-process research and development (IPR&D) financial
"in-process research and development (IPR&D) assets acquired in a business combination"
In-process research and development (IPR&D) is the value assigned to research projects a company buys from another firm that are not yet finished or approved. Think of it as purchasing a half-completed recipe that might become a bestseller or never work out; investors care because it represents future potential products and revenue but also carries risk of failure or one-time write-offs that can affect a company’s reported profits and valuation.
replacement share-based payment awards financial
"accounted for as replacement share-based payment awards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were PALX’s revenue and net loss for the first nine months of 2026?

PALX reported no revenue and a net loss of $7.028 million for the nine months ended September 30, 2026. The net loss was $2.422 million for the same period in 2025. The company said it remained in the development stage.

What were the terms of PALX’s April 2026 private placement?

At the April 20, 2026 initial closing, PALX sold 3,773,853 common shares at $4.00 per share and issued 374,761 warrants in connection with the offering. On April 30, 2026, PALX sold 470,000 additional shares for $1.9 million in gross proceeds.

How much stock-based compensation cost remained unrecognized at PALX?

As of September 30, 2026, PALX had $17.4 million of unrecognized compensation cost for stock options, restricted stock awards, restricted stock units and Vega Links consideration shares, expected to be recognized over a weighted-average period of 3.4 years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false Q3 --12-31 0001938569 0001938569 2026-01-01 2026-09-30 0001938569 2026-11-13 0001938569 2026-09-30 0001938569 2025-12-31 0001938569 2026-07-01 2026-09-30 0001938569 2025-07-01 2025-09-30 0001938569 2025-01-01 2025-09-30 0001938569 us-gaap:CommonStockMember 2025-12-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001938569 us-gaap:RetainedEarningsMember 2025-12-31 0001938569 us-gaap:CommonStockMember 2026-03-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001938569 us-gaap:RetainedEarningsMember 2026-03-31 0001938569 2026-03-31 0001938569 us-gaap:CommonStockMember 2026-06-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001938569 us-gaap:RetainedEarningsMember 2026-06-30 0001938569 2026-06-30 0001938569 us-gaap:CommonStockMember 2023-12-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001938569 us-gaap:RetainedEarningsMember 2023-12-31 0001938569 2023-12-31 0001938569 us-gaap:CommonStockMember 2024-12-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001938569 us-gaap:RetainedEarningsMember 2024-12-31 0001938569 2024-12-31 0001938569 us-gaap:CommonStockMember 2025-03-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001938569 us-gaap:RetainedEarningsMember 2025-03-31 0001938569 2025-03-31 0001938569 us-gaap:CommonStockMember 2025-06-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001938569 us-gaap:RetainedEarningsMember 2025-06-30 0001938569 2025-06-30 0001938569 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001938569 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001938569 2026-01-01 2026-03-31 0001938569 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001938569 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001938569 2026-04-01 2026-06-30 0001938569 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001938569 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001938569 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001938569 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001938569 2024-01-01 2024-12-31 0001938569 2024-01-01 2025-12-31 0001938569 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001938569 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001938569 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001938569 2025-01-01 2025-03-31 0001938569 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001938569 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001938569 2025-04-01 2025-06-30 0001938569 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001938569 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001938569 us-gaap:CommonStockMember 2026-09-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001938569 us-gaap:RetainedEarningsMember 2026-09-30 0001938569 us-gaap:CommonStockMember 2025-09-30 0001938569 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001938569 us-gaap:RetainedEarningsMember 2025-09-30 0001938569 2025-09-30 0001938569 PALX:VegaLinksIncMember 2026-09-30 0001938569 2025-09-29 0001938569 PALX:PerformanceBasedRestrictedStockUnitsMember 2026-01-01 2026-09-30 0001938569 PALX:UnvestedRestrictedStockAwardsMember 2026-01-01 2026-09-30 0001938569 PALX:UnvestedRestrictedStockAwardsMember 2025-01-01 2025-09-30 0001938569 PALX:UnvestedRestrictedStockUnitsMember 2026-01-01 2026-09-30 0001938569 PALX:UnvestedRestrictedStockUnitsMember 2025-01-01 2025-09-30 0001938569 us-gaap:OptionMember 2026-01-01 2026-09-30 0001938569 us-gaap:OptionMember 2025-01-01 2025-09-30 0001938569 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001938569 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001938569 PALX:GeneralAndAdministrativeExpensesMember 2026-07-01 2026-09-30 0001938569 PALX:GeneralAndAdministrativeExpensesMember 2025-07-01 2025-09-30 0001938569 PALX:GeneralAndAdministrativeExpensesMember 2026-01-01 2026-09-30 0001938569 PALX:GeneralAndAdministrativeExpensesMember 2025-01-01 2025-09-30 0001938569 PALX:ResearchAndDevelopmentsExpensesMember 2026-07-01 2026-09-30 0001938569 PALX:ResearchAndDevelopmentsExpensesMember 2025-07-01 2025-09-30 0001938569 PALX:ResearchAndDevelopmentsExpensesMember 2026-01-01 2026-09-30 0001938569 PALX:ResearchAndDevelopmentsExpensesMember 2025-01-01 2025-09-30 0001938569 PALX:VegaLinksIncMember 2026-07-31 0001938569 PALX:VegaLinksIncMember 2026-07-31 2026-07-31 0001938569 PALX:VegaLinksIncMember 2026-01-01 2026-09-30 0001938569 PALX:VegaLinksIncMember 2026-07-01 2026-09-30 0001938569 PALX:VegaLinksIncMember 2025-07-01 2025-09-30 0001938569 PALX:VegaLinksIncMember 2025-01-01 2025-09-30 0001938569 PALX:LaptopsAndITEquipmentMember 2026-09-30 0001938569 PALX:LaptopsAndITEquipmentMember 2025-12-31 0001938569 PALX:ITEquipmentMember 2026-09-30 0001938569 us-gaap:FurnitureAndFixturesMember 2026-09-30 0001938569 us-gaap:FurnitureAndFixturesMember 2025-12-31 0001938569 us-gaap:EquipmentMember 2026-09-30 0001938569 us-gaap:EquipmentMember 2025-12-31 0001938569 us-gaap:ConstructionInProgressMember 2026-09-30 0001938569 us-gaap:ConstructionInProgressMember 2025-12-31 0001938569 PALX:DaltonDenBaarsMember 2025-10-15 2025-10-15 0001938569 PALX:DaltonDenBaarsMember 2026-09-30 0001938569 PALX:DaltonDenBaarsMember 2025-12-31 0001938569 PALX:DaltonDenBaarsMember 2026-07-01 2026-09-30 0001938569 PALX:DaltonDenBaarsMember 2025-07-01 2025-09-30 0001938569 PALX:DaltonDenBaarsMember 2026-01-01 2026-09-30 0001938569 PALX:DaltonDenBaarsMember 2025-01-01 2025-09-30 0001938569 PALX:StevenDenbaarsMember 2026-09-30 0001938569 PALX:StevenDenbaarsMember 2025-12-31 0001938569 PALX:StevenDenbaarsMember 2026-07-01 2026-09-30 0001938569 PALX:StevenDenbaarsMember 2026-01-01 2026-09-30 0001938569 PALX:JeffreyShealyMember 2026-09-30 0001938569 PALX:JeffreyShealyMember 2026-07-01 2026-09-30 0001938569 PALX:JeffreyShealyMember 2026-01-01 2026-09-30 0001938569 PALX:JeffreyShealyMember 2025-07-01 2025-09-30 0001938569 PALX:JeffreyShealyMember 2025-01-01 2025-09-30 0001938569 PALX:ConsultingAgreementMember 2025-10-01 2025-10-01 0001938569 PALX:ConsultingAgreementMember PALX:MsHonickMember 2025-10-01 2025-10-01 0001938569 PALX:ConsultingAgreementMember 2026-07-01 2026-09-30 0001938569 PALX:ConsultingAgreementMember 2026-01-01 2026-09-30 0001938569 us-gaap:PerformanceSharesMember PALX:MsHonickMember 2026-07-01 2026-07-31 0001938569 us-gaap:PerformanceSharesMember PALX:MsHonickMember 2026-07-31 0001938569 us-gaap:PerformanceSharesMember PALX:MsHonickMember 2026-07-01 2026-09-30 0001938569 us-gaap:PerformanceSharesMember PALX:MsHonickMember 2026-01-01 2026-09-30 0001938569 PALX:ConsultingAgreementMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-01-31 0001938569 us-gaap:RestrictedStockUnitsRSUMember PALX:JamesShealyMember 2026-09-22 0001938569 us-gaap:RestrictedStockUnitsRSUMember PALX:JamesShealyMember 2026-09-22 2026-09-22 0001938569 PALX:ConsultingAgreementMember PALX:MsNguyenMember 2025-10-01 2025-10-01 0001938569 PALX:ConsultingAgreementMember PALX:MsNguyenMember 2025-01-01 2025-12-31 0001938569 PALX:ConsultingAgreementMember PALX:MsNguyenMember 2026-07-01 2026-09-30 0001938569 PALX:ConsultingAgreementMember PALX:MsNguyenMember 2026-01-01 2026-09-30 0001938569 PALX:ConsultingAgreementMember PALX:MsNguyenMember 2026-09-30 0001938569 us-gaap:PerformanceSharesMember PALX:MsNguyenMember 2026-07-31 2026-07-31 0001938569 us-gaap:PerformanceSharesMember PALX:MsNguyenMember 2026-07-31 0001938569 us-gaap:PerformanceSharesMember PALX:MsNguyenMember 2026-07-01 2026-09-30 0001938569 us-gaap:PerformanceSharesMember PALX:MsNguyenMember 2026-01-01 2026-09-30 0001938569 PALX:MrRichardOgawaMember 2026-07-31 2026-07-31 0001938569 PALX:MrMaggieNguyenMember 2026-07-31 2026-07-31 0001938569 PALX:MrRichardOgawaMember 2026-09-30 2026-09-30 0001938569 PALX:MrMaggieNguyenMember 2026-09-30 2026-09-30 0001938569 PALX:MrKarthikGopalakrishnanMember 2026-09-30 2026-09-30 0001938569 PALX:MrKarthikGopalakrishnanMember PALX:UnsecuredLoanAgreementMember PALX:VegaLinksIncMember 2026-02-28 0001938569 PALX:MrKarthikGopalakrishnanMember PALX:UnsecuredLoanAgreementMember 2026-09-24 2026-09-24 0001938569 2025-11-26 0001938569 2026-07-16 2026-07-16 0001938569 2026-07-16 0001938569 PALX:SubscriptionAgreementMember us-gaap:PrivatePlacementMember 2026-04-20 2026-04-20 0001938569 PALX:SubscriptionAgreementMember us-gaap:PrivatePlacementMember 2026-04-20 0001938569 PALX:SubscriptionAgreementMember us-gaap:InvestorMember 2026-04-30 2026-04-30 0001938569 us-gaap:WarrantMember 2026-09-30 0001938569 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001938569 2026-07-31 2026-07-31 0001938569 PALX:TwoThousandTwentyFiveEquityIncentivePlanMember 2025-01-01 2025-12-31 0001938569 2026-07-11 2026-07-11 0001938569 PALX:PerformanceBasedRestrictedStockUnitsMember 2026-09-22 2026-09-22 0001938569 PALX:RestrictedAwardsAndStockOptionsMember 2026-09-30 0001938569 PALX:RestrictedAwardsAndStockOptionsMember 2026-01-01 2026-09-30 0001938569 PALX:RestrictedStockAwardsMember 2026-01-01 2026-09-30 0001938569 us-gaap:RestrictedStockUnitsRSUMember 2026-01-01 2026-09-30 0001938569 PALX:RestrictedStockAwardsMember 2025-12-31 0001938569 PALX:RestrictedStockAwardsMember 2026-09-30 0001938569 us-gaap:RestrictedStockUnitsRSUMember 2025-12-31 0001938569 us-gaap:RestrictedStockUnitsRSUMember 2026-09-30 0001938569 PALX:PerformanceBasedRestrictedStockUnitsMember 2025-12-31 0001938569 PALX:PerformanceBasedRestrictedStockUnitsMember 2026-09-30 0001938569 us-gaap:ResearchAndDevelopmentExpense 2026-07-01 2026-09-30 0001938569 us-gaap:ResearchAndDevelopmentExpense 2025-07-01 2025-09-30 0001938569 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0001938569 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0001938569 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001938569 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001938569 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001938569 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001938569 us-gaap:SubsequentEventMember PALX:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-11-05 0001938569 us-gaap:SubsequentEventMember PALX:TwoThousandTwentyFiveEquityIncentivePlanMember 2026-11-05 2026-11-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PALX:Segment

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

For the Quarterly Period Ended September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number: 000-56582

 

PALOMINO LABORATORIES INC.

(Exact name of registrant as specified in its charter)

 

Delaware   88-1619619
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

130 Castilian Drive, Suite 102    
Goleta, CA    93117
(Address of principal executive offices)   (Zip Code)

 

(704) 756-2981

 

(Registrant’s telephone number, including area code) 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File to be submitted posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company filer. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated Filer ☒ Smaller reporting company ☒
    Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

As of November 13, 2026, the registrant had 27,636,539 shares of common stock issued and outstanding.

 

 

 

 

 

 

PALOMINO LABORATORIES INC.

QUARTERLY REPORT ON FORM 10-Q

SEPTEMBER 30, 2026

 

TABLE OF CONTENTS

 

  Page
   
PART I – FINANCIAL INFORMATION 3
     
Item 1. Financial Statements. 3
  Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 5
  Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months ended September 30, 2026 and 2025 6
  Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) for the Three and Nine months ended September 30, 2026 and 2025 7
  Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine months ended September 30, 2026 and 2025  8
  Notes to Unaudited Condensed Consolidated Financial Statements 9
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 25
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk. 32
     
Item 4. Controls and Procedures. 32
     
PART II – OTHER INFORMATION 34
     
Item 1. Legal Proceedings. 34
     
Item 1A. Risk Factors. 34
     
Item 2. Unregistered Sales of Equity Securities. 34
     
Item 3. Defaults Upon Senior Securities. 34
     
Item 4. Mine Safety Disclosures. 34
     
Item 5. Other Information. 34
     
Item 6. Exhibits. 34
     
SIGNATURES 35

 

2
 

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

 

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our financial statements and the accompanying notes thereto included elsewhere in this quarterly report on Form 10-Q (the “Quarterly Report”).

 

The registrant was incorporated as Unite Acquisition 3 Corp. (“Unite Acquisition” or “Unite”) in the State of Delaware on March 10, 2022. Prior to the Merger (as defined below), the registrant was a “shell company” (as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)).

 

On September 29, 2025, Unite Acquisition’s wholly owned subsidiary, Palomino Acquisition Co., a Delaware corporation formed in the State of Delaware on August 19, 2025, (“Merger Sub”), merged with and into Palomino Laboratories Inc., a privately held Delaware corporation (“Private Palomino”). Pursuant to this transaction (the “Merger”), Private Palomino was the surviving corporation and became the Company’s wholly owned subsidiary, and all of the outstanding stock of Private Palomino was converted into shares of the combined Company’s common stock, par value $0.0001 per share. In addition, in connection with the Merger, all of Private Palomino’s outstanding simple agreements for future equity (“SAFEs”) converted into shares of common stock and warrants at $1.5 per share and all of Private Palomino’s outstanding warrants became exercisable for shares of common stock.

 

As a result of the Merger, we acquired the business of Private Palomino and continued its business operations as a public reporting company under the same name, Palomino Laboratories Inc. Concurrent with the consummation of the Merger, Private Palomino changed its name to “Rhino Subsidiary Inc.”

 

In accordance with “reverse merger” or “reverse acquisition” accounting treatment, our historical financial statements as of period ends, and for periods ended, prior to the Merger have been replaced with the historical financial statements of Private Palomino prior to the Merger, in this Report.

 

This Quarterly Report contains forward-looking statements. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. This information may involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from the future results, performance or achievements expressed or implied by any forward-looking statements.

 

We cannot predict all of the risks and uncertainties. Accordingly, such information should not be regarded as representations that the results or conditions described in such statements or that our objectives and plans will be achieved and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements. These forward-looking statements include information concerning possible or assumed future results of our operations, including statements about our business strategies; future cash flows; financing plans; plans and objectives of management; any other statements regarding future acquisitions, future cash needs, future operations, business plans and future financial results, our ability to obtain or maintain patents or other appropriate protection for our intellectual property, and any other statements that are not historical facts.

 

These statements are only predictions and involve known and unknown risks, uncertainties and other factors. Readers are urged to carefully review and consider the various disclosures made by us in this Quarterly Report and in our other reports filed with the Securities and Exchange Commission (the “SEC”). Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements.

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and the rules of the SEC and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in our Annual Report on Form 10-K for the year ended December 31, 2025, which were filed with the Securities and Exchange Commission (“SEC”) on March 31, 2026. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the periods presented have been reflected herein. The results of operations for the periods presented are not necessarily indicative of the results to be expected for the year ending December 31, 2026 or for any other interim period or future year.

 

3
 

 

PALOMINO LABORATORIES INC.

CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

SEPTEMBER 30, 2026 (UNAUDITED)

 

INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Statement   Page
     
Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025   5
     
Condensed Consolidated Statements of Operations (Unaudited) for the Three and Nine Months ended September 30, 2026 and 2025   6
     
Condensed Consolidated Statements of Changes in Stockholders’ Equity (Unaudited) for the Three and Nine Months ended September 30, 2026 and 2025   7
     
Condensed Consolidated Statements of Cash Flows (Unaudited) for the Nine Months ended September 30, 2026 and 2025   8
     
Notes to Unaudited Condensed Consolidated Financial Statements   9

 

4
 

 

palomino laboratories inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(all amounts in thousands of USD, except number of shares and per share data)

 

   (Unaudited)     
   September 30,   December 31, 
   2026   2025 
         
Assets          
Current assets:          
Cash and cash equivalents  $17,788   $8,121 
Prepaids and other current assets   108    313 
Total current assets   17,896    8,434 
Property and equipment, net   1,378    - 
Right-of-use assets, net   329    - 
Intangible assets - IPR&D   21    - 
Goodwill   26    - 
Other assets   45    - 
Total assets  $19,695   $8,434 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable  $362   $56 
Accrued expenses and other liabilities   410    281 
Liability for unvested restricted stock, current   18    - 
Operating lease liability, current   157    - 
Total current liabilities   947    337 
Operating lease liability, noncurrent   178    - 
Liability for unvested restricted stock, noncurrent   38    - 
Deferred tax liability   2    - 
Total liabilities   1,165    337 
           
Commitments and contingencies (Note 7)   -    - 
           
Stockholders’ equity:          
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at September 30, 2026 and December 31, 2025   -    - 
Common stock, $0.0001 par value; 300,000,000 shares authorized; 27,636,539 and 18,770,686 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively   2    2 
Additional paid-in capital   28,738    11,277 
Accumulated deficit   (10,210)   (3,182)
Total stockholders’ equity   18,530    8,097 
Total liabilities and stockholders’ equity  $19,695   $8,434 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5
 

 

Palomino laboratories inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(all amounts in thousands of USD, except number of shares and per share data)

(Unaudited)

 

    2026    2025    2026    2025 
  

Three months ended September 30,

  

Nine months ended September 30,

 
    2026    2025    2026    2025 
                     
Operating expenses:                    
General and administrative  $2,618   $1,605   $4,120   $1,962 
Research and development   1,803    -    2,910    - 
Total operating expenses   4,421    1,605    7,030    1,962 
Loss from operations   (4,421)   (1,605)   (7,030)   (1,962)
Other income (expense):                    
Change in fair value of SAFE notes   -    (220)   -    (461)
Interest income   -    -    1    1 
Total other income (expense)   -    (220)   1    (460)
                     
Income tax benefit   1    -    1    - 
Net loss  $(4,420)  $(1,825)  $(7,028)  $(2,422)
                     
Net loss per common share - basic and diluted  $(0.19)  $(0.54)  $(0.33)  $(0.88)
Weighted average common shares outstanding - basic and diluted   22,823,051    3,383,919    21,067,084    2,735,263 

 

The accompanying notes are an integral part of these condensed consolidated financial statements. 

 

6
 

 

palomino laboratories inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(all amounts in thousands of USD, except number of shares and per share data)

(Unaudited)

 

   Shares   Amount  

Capital

  

Deficit

  

Equity

 
   Common Stock  

Additional

Paid-In

   Accumulated  

Total

Stockholders’

 
   Shares   Amount  

Capital

  

Deficit

  

Equity

 
Balance, December 31, 2025   18,770,686   $2   $11,277   $(3,182)  $8,097 
Stock-based compensation expense   -    -    155    -    155 
Issuance of restricted stock awards   150,000    -    -    -    - 
Net loss   -    -    -    (1,243)   (1,243)
Balance, March 31, 2026   18,920,686    2    11,432    (4,425)   7,009 
Stock-based compensation expense   -    -    101    -    101 
Issuance of common shares, net of issuance costs of $2,154   4,243,853    -    14,821    -    14,821 
Net loss   -    -    -    (1,365)   (1,365)
Balance, June 30, 2026   23,164,539    2    26,354    (5,790)   20,566 
Stock-based compensation expense   -    -    2,355    -    2,355 
Issuance of common stock in acquisition of Vega Links Inc. (4,386,666 unvested)   4,472,000    -    29    -    29 
Net loss   -    -    -    (4,420)   (4,420)
Balance, September 30, 2026   27,636,539   $2   $28,738   $(10,210)  $18,530 

 

   Common Stock  

Additional

Paid-In

   Accumulated  

Total

Stockholders’

Equity

 
   Shares   Amount  

Capital

  

Deficit

  

(Deficit)

 
Balance, December 31, 2024   6,000,000   $-   $-   $(17)  $(17)
Retroactive application of recapitalization   (1,500,000)   -    -    -    - 
Balance, December 31, 2024   4,500,000    -    -    (17)   (17)
Stock-based compensation expense   -    -    12    -    12 
Issuance of restricted stock awards   1,500,000    -    -    -    - 
Net loss   -    -    -    (985)   (985)
Balance, March 31, 2025   6,000,000    -    12    (1,002)   (990)
Stock-based compensation expense   -    -    155    -    155 
Net income   -    -    -    388    388 
Balance, June 30, 2025   6,000,000    -    167    (614)   (447)
Common stock and warrants issued in connection with SAFE conversion   1,537,501    -    2,306    -    2,306 
Sale of common stock and warrants in the private placement, net of issuance costs of $1,596   5,344,623    1    6,421    -    6,422 
Equity of Unite Acquisition 3 Corp. at the time of the exchange   5,000,000    1    (1)   (398)   (398)
Common stock cancelled at the time of the exchange   (1,000,000)   -    -    -    - 
Recapitalization of Unite Acquisition 3 Corp. accumulated deficit at time of the exchange   -    -    (398)   398    - 
Stock-based compensation expense   -    -    1,074    -    1,074 
Issuance of restricted stock awards in exchange for pre-Merger services   370,834    -    183    -    183 
Issuance of restricted stock awards in exchange for future services   358,334    -    -    -    - 
Net loss   -    -    -    (1,825)   (1,825)
Balance, September 30, 2025   17,611,292   $2   $9,752   $(2,439)  $7,315 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

7
 

 

palomino laboratories inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(all amounts in thousands of USD)

(Unaudited)

 

   2026   2025 
  

For the Nine Months Ended September 30,

 
   2026   2025 
         
Cash flows from operating activities:          
Net loss  $(7,028)  $(2,422)
Adjustments to reconcile net loss to net cash used in operating activities:          
Stock-based compensation related to employees and non-employees   2,611    1,424 
Depreciation expense   32    - 
Change in fair value of SAFE notes   -    461 
Deferred income tax benefit from release of valuation allowance   (1)   - 
Changes in operating assets and liabilities:          
Prepaids and other assets   161    (411)
Accounts payable   279    58 
Accrued expenses and other liabilities   129    499 
Change in right of use and lease liability   6    - 
Net cash used in operating activities   (3,811)   (391)
           
Cash flows from investing activities:          
Purchase of property and equipment   (1,388)   - 
Cash acquired in acquisition of Vega Links Inc.   70    - 
Net cash used in investing activities   (1,318)   - 
           
Cash flows from financing activities:          
Proceeds from sale of common stock and warrants in private placement   16,975    8,017 
Proceeds from issuance of SAFE notes   -    1,695 
Payment of offering cost related to private placement   (2,154)   (1,559)
Repayment of shareholder loans assumed in acquisition   (25)   - 
Net cash provided by financing activities   14,796    8,153 
           
Net increase in cash and cash equivalents   9,667    7,762 
Cash and cash equivalents at beginning of the period   8,121    135 
Cash and cash equivalents at end of the period  $17,788   $7,897 
           
Supplemental schedule of non-cash activities:          
Right of use asset acquired in exchange for lease liability  $376   $- 
Unpaid transaction costs   -    37 
Common stock issued in acquisition of Vega Links, Inc.   29    - 
Purchase of property and equipment included in accounts payable   19    - 
Recapitalization of Unite Acquisition 3 Corp. accumulated deficit at time of the exchange   -    (398)
Conversion of SAFE notes   -    2,306 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

8
 

 

palomino laboratories inc.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 

Note 1. Nature of Operations and Liquidity

 

Business Description

 

Palomino Laboratories Inc. (post-merger), formerly Unite Acquisition 3 Corp., (the “Company”) was incorporated in the State of Delaware on February 9, 2023. The Company’s management has chosen December 31 for its fiscal year end. In 2025, pre-merger Palomino Laboratories Inc. (“Private Palomino”) changed its name, concurrent with the consummation of the Merger, to Rhino Subsidiary Inc.

 

On September 29, 2025, Unite Acquisition 3 Corp.’s (“Unite”) wholly owned subsidiary, Palomino Acquisition Co., a Delaware corporation formed in the State of Delaware on August 19, 2025 (“Merger Sub”), merged with and into Private Palomino, a privately held Delaware corporation. Pursuant to this transaction (the “Merger”), Private Palomino was renamed to Rhino Subsidiary Inc. and became the Company’s wholly owned subsidiary and all of the outstanding stock of Private Palomino was converted into shares of the Company’s common stock, par value $0.0001 per share. As a result, Unite ceased to be a shell company and continues as a public reporting company under the new name, Palomino Laboratories Inc.

 

The Merger was accounted for as a reverse recapitalization as Private Palomino was determined to be the accounting acquirer under Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 805, Business Combinations.

 

Upon the completion of the Merger between the Private Palomino and Unite, the share, per share value and net loss per share in the accompanying consolidated financial statements for all dates prior to the Merger were retroactively recast to reflect the exchange ratio pursuant to the Merger.

 

The Company is a fabless semiconductor company pioneering the next generation of high-performance microLED-based optoelectronic solutions for data communication. Its mission is to enable ultra-high-speed, energy-efficient optical interconnects that replace legacy copper-based PCIe and Ethernet links in compute-intensive environments. The Company is commercializing a breakthrough platform built on advanced gallium nitride (GaN) compound semiconductor materials. This proprietary technology enables scalable and cost-efficient manufacturing of ultra-compact, high-speed optical transceivers, with significant improvements in power, size, and bandwidth density over traditional laser-based solutions. The Company’s differentiated value proposition lies in leveraging high-efficiency microLEDs as optical sources in transceiver modules that can be seamlessly integrated into silicon packages or interposers. This approach unlocks the potential for high-density, chip-scale optical I/O—fundamentally reshaping the future of data movement in AI servers, data centers, and high-performance computing systems. On July 31, 2026, the Company acquired Vega Links Inc., a developer of semiconductor integrated circuits for high-speed interconnects. The acquisition expands the Company’s optical interconnect platform with Vega Links’ high-speed interconnect integrated circuit and digital signal processing technology and adds its engineering team (See Note 3, Business Combination). During the nine months ended September 30, 2026 and 2025, the Company did not earn revenues and was considered in the development stage. However, the Company is in process of setting up revenue generating operations.

 

Liquidity

 

Since its inception, the Company has incurred net losses and negative cash flows from operations. As of September 30, 2026, the Company had an accumulated deficit of $10.2 million and incurred net losses of $7.0 million and $2.4 million during the nine months ended September 30, 2026 and 2025, respectively.

 

As of September 30, 2026, the Company had a balance of cash and cash equivalents of $17.8 million. The Company believes that its existing cash and cash equivalents balance will be sufficient to support operations for at least one year from the issuance date of these unaudited condensed consolidated financial statements.

 

The Company expects to incur additional losses and negative cash flows for the foreseeable future as it continues to hire additional personnel, protect its intellectual property and grow its business. The Company may need to raise additional capital to support its continuing operations and pursue its long-term business plan. Financing activities may include, but are not limited to, public or private equity offerings, debt financing, or other sources. Such activities are subject to significant risks and uncertainties.

 

9
 

 

Note 2. Basis of Presentation and Summary of Significant Accounting Policies

 

The following is a summary of significant accounting policies consistently applied during the preparation of the accompanying unaudited condensed consolidated financial statements.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the unaudited condensed consolidated financial statements) considered necessary to present fairly the Company’s condensed consolidated balance sheets as of September 30, 2026 and December 31, 2025, its condensed consolidated statements of operations and stockholders’ equity for the three and nine months ended September 30, 2026 and 2025, and its condensed consolidated cash flows for the nine months ended September 30, 2026 and 2025. The unaudited condensed consolidated financial statements, presented herein, do not contain all of the disclosures required under accounting principles generally accepted in the United States of America (“GAAP”) for annual financial statements. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the annual consolidated financial statements and related notes as of and for the year ended December 31, 2025. The December 31, 2025 balance sheet presented in these unaudited condensed consolidated financial statements has been derived from the Company’s Annual Report on Form 10-K, which were filed with SEC on March 31, 2026. The operating results for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or any other interim period.

 

Basis of Presentation and Principles of Consolidation

 

The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and include the accounts of the Company’s consolidated subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The accompanying unaudited condensed consolidated financial statements have also been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. These unaudited condensed consolidated financial statements are presented in United States Dollar (“USD”).

 

Emerging Growth Company

 

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934 (the “Exchange Act”) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when an accounting standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised accounting standards.

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.

 

Estimates and assumptions are periodically reviewed, and the effects of the revisions are reflected in the accompanying unaudited condensed consolidated financial statements in the period they are determined to be necessary. Significant estimates and assumptions made in the accompanying unaudited condensed consolidated financial statements include, but are not limited to, realization of deferred tax assets, useful lives of assets, impairment of assets, incremental borrowing rate for leases, purchase price allocations, including fair value estimates of intangible assets, goodwill and the valuation and expensing of share-based awards.

 

10
 

 

Fair Value Measurements

 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The fair value standard outlines a valuation framework and creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the related disclosures. The Company uses the hierarchy prescribed in the accounting guidance for fair value measurements, based upon the available inputs to the valuation and the degree to which they are observable or not observable in the market. The three levels in the hierarchy are as follows:

 

  ● Level 1 - Quoted prices (unadjusted) for identical assets or liabilities in active markets that are accessible as of the measurement date;
     
  ● Level 2 - Inputs other than quoted prices in active markets for identical assets and liabilities that are observable either directly or indirectly for substantially the full term of the asset or liability; and
     
  ● Level 3 - Unobservable inputs reflecting the Company’s own assumptions about the assumptions that market participants would use in pricing the asset or liability, including assumptions about risk.

 

The carrying amounts of certain financial assets and liabilities, including prepaid and other current assets, accounts payable and accrued liabilities approximate fair value because of the short maturity and liquidity of those instruments. The carrying amount of the liability for unvested restricted stock, including its noncurrent portion, approximates fair value because it represents the cash received for unvested restricted stock, which would be repaid at the original purchase price if the Company repurchases those shares. The classification of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement in its entirety.

 

Concentration of Credit Risk

 

Financial instruments that potentially subject the Company to credit risk consist primarily of cash and cash equivalents, which at times, may exceed the Federal Deposit Insurance Corporation (“FDIC”) insurance limit of $250,000. The Company holds cash at financial institutions that the Company believes are good credit, quality financial institutions and limits the amount of credit exposure with any one bank and conducts ongoing evaluations of the creditworthiness of the banks with which it does business.

 

Significant Risks and Uncertainties Including Business Risks

 

The Company is an early-stage, fabless semiconductor company that has not yet generated revenue. Although the Company has established business operations, including leased facilities, property and equipment and ongoing research and development activities, and acquired Vega Links (see Note 3, Business Combination), the Company has a limited operating history upon which to evaluate the business and future prospects, which subjects it to a number of risks and uncertainties, including its ability to complete the development and commercialization of its products, integrate the operations of Vega Links, and plan for and predict future growth.

 

The Company may need to raise additional capital to support its development and commercialization activities. Significant risks and uncertainties to the Company’s operations include failing to secure additional funding and the threat of other companies developing and bringing to market similar technology at an earlier time than the Company.

 

Property and Equipment, net

 

Property and equipment, net is recorded at cost, less accumulated depreciation. Expenditures for repairs and maintenance of capitalized assets associated with research & development functions, that do not improve or extend the life of the assets are charged to research and development expense as incurred only if those assets relate to research and development. Maintenance for general property and equipment like computers and furniture and fixtures are expensed in general and administrative expense. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. The Company recognizes depreciation expense in research and development expense if the related property and equipment, net is used for research and development purposes. Otherwise, depreciation expense is recorded in general and administrative expense.

 

11
 

 

Construction in progress (CIP) is recorded at historical cost. The historical cost of acquiring an asset includes the costs necessarily incurred to bring it to the condition and location necessary for its intended use. Where an asset requires a period of time to carry out the activities necessary to bring it to that condition and location, the costs incurred during that period form part of the asset’s historical cost. When a CIP asset is substantially complete and ready for its intended use, its accumulated cost is transferred from CIP to the appropriate PP&E asset. Depreciation begins at that point. CIP is not depreciated while under construction. Depreciation expense for an asset is determined based on the asset’s useful life.

 

The Company evaluates the net realizable value of long-lived assets whenever events or changes in circumstances indicate the carrying value of the assets may not be recoverable. If such indicators are present, the Company determines whether the sum of the estimated undiscounted future cash flows attributable to such assets is less than their carrying amount, and if so, the Company recognizes an impairment loss based on the excess of the carrying value of the assets over their fair value. No circumstances or events indicated impairment to property and equipment as of September 30, 2026 and December 31, 2025 or during the three and nine months ended September 30, 2026 and 2025.

 

Leases

 

The Company determines whether a contract is or contains a lease at inception in accordance with ASC 842, Leases. Operating leases are recognized on the unaudited condensed consolidated balance sheet as right-of-use (“ROU”) assets and lease liabilities. ROU assets represent the Company’s right to use the underlying leased asset over the lease term.

 

Lease liabilities are measured at the present value of lease payments not yet paid, discounted using the Company’s incremental borrowing rate (“IBR”) at the commencement date (or the effective date of a modification, as applicable), as the rate implicit in the Company’s leases is not readily determinable. The IBR is the rate of interest that the Company would have to pay to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment. ROU assets are measured at the amount of the lease liability, adjusted for any lease payments made at or before commencement, lease incentives received, and initial direct costs incurred.

 

Lease terms include the noncancellable period of the lease plus any periods covered by options to extend (or not terminate) the lease that the Company is reasonably certain to exercise. The Company evaluates renewal and termination options at lease commencement and upon occurrence of a triggering event. When the Company exercises a renewal option that was not previously included in the lease term, the lease is remeasured as of the modification date using the IBR in effect at that date.

 

Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease payments that do not depend on an index or rate, including the Company’s share of building operating expenses and common area maintenance charges, are expensed as incurred and are not included in the measurement of lease liabilities. The Company may enter into leases with an initial term of 12 months or less (“Short-Term Leases”). For Short-Term Leases, the Company records the rent expense on a straight-line basis and does not record the leases on the unaudited condensed consolidated balance sheet. There were no Short-term Leases as of September 30, 2026 and December 31, 2025.

 

Share-based compensation

 

The Company measures equity classified share-based awards granted to employees, non-employees and directors based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is the vesting period of the respective award. The Company accounts for forfeitures as they occur. For share-based awards with service-based vesting conditions, the Company recognizes compensation expense on a straight-line basis over the service period. Compensation cost for awards granted to non-employees is recognized as if the Company had paid cash for the services; for non-employee awards with graded vesting, each separately vesting tranche is treated as a separate award and is recognized from the service inception date to its vesting date. For stock options with performance conditions, compensation cost is recognized when it is probable that the performance conditions will be achieved. The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Fair value is determined using a combination of the probability weighted expected return method and option pricing model. The Company’s share-based awards consist of restricted stock awards (“RSAs”), restricted stock units (“RSUs”), performance-based restricted stock units (“PSUs”), service-based stock options and performance-based stock options. The fair value of RSAs, RSUs and PSUs are measured based on the grant-date fair value of the restricted stock awards.

 

Stock options fair value is measured using the Black-Scholes-Merton option pricing model consists of the following inputs: the expected term of the stock options is estimated using the “simplified method” as the Company does not have sufficient historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.

 

Estimating the fair value of share-based award requires the input of subjective assumptions, including the estimated fair value of the Company’s common stock. The assumptions used in estimating the fair value of share-based awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

 

12
 

 

Liability for unvested restricted stock

 

The Consideration Shares issued in the acquisition of Vega Links remain subject to the stock purchase agreements that the Company assumed from Vega Links. Under those agreements, if a holder ceases to provide services to the Company, the Company may repurchase the holder’s unvested shares within 90 days at the holder’s original purchase price, and the repurchase right is deemed exercised automatically unless the Company elects not to exercise it. Because the Company can reacquire unvested shares for the amount the holder paid, the cash received for unvested shares is not considered an equity issuance until the shares vest and is recorded as a liability for unvested restricted stock. As the shares vest, the related portion of the liability is reclassified to common stock and additional paid-in capital. If unvested shares are repurchased, the purchase price is refunded and the related liability is extinguished. The portion of the liability related to shares scheduled to vest within twelve months of the balance sheet date under each award’s contractual vesting schedule is classified as current, and the remainder is classified as noncurrent. As of September 30, 2026, the liability for unvested restricted stock was $18 thousand current and $38 thousand noncurrent, related to 4,360,000 unvested Consideration Shares.

 

In connection with the restricted stock awards, each grantee made an election under Section 83(b) of the Internal Revenue Code of 1986, as amended (the “Code”), to recognize compensation income in the year of purchase equal to the excess, if any, of the fair market value of the shares on the purchase date, determined without regard to any restrictions other than restrictions that will never lapse, over the purchase price paid. The elections are tax elections made by the grantees and do not affect the Company’s accounting for the restricted stock awards under ASC 718.

 

Research and development

 

Research and development represent costs incurred to develop the Company’s technologies. These costs consist of personnel costs, including salaries, employee benefit costs, stock-based compensation expenses, lease expenses, university contribution expense, nanofabrication lab usage expense as well as depreciation and amortization expense for capitalized assets associated with these functions. The Company expenses all research and development costs in the periods in which they are incurred.

 

Net loss per share

 

The Company adopted ASC 260, “Earnings per Share”, at its inception. Basic net loss per share of common stock is computed by dividing net loss by the weighted-average number of shares of common stock outstanding during each period. Diluted net loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, potentially dilutive securities are not included in the calculation when the impact is anti-dilutive.

 

The computation below excludes 1,600,000 performance-based restricted stock units granted. These units are contingently issuable shares whose performance conditions had not been satisfied at September 30, 2026, and accordingly they were not included in the computation of diluted net loss per share.

 

The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding, as they would be anti-dilutive:

 

   2026   2025 
  

For the Nine Months Ended September 30,

 
   2026   2025 
         
Unvested restricted stock awards   4,703,750    358,334 
Unvested restricted stock units   133,750    - 
Stock options   1,820,000    - 
Warrants   9,141,055    7,493,461 
Total   15,798,555    7,851,795 

 

13
 

 

Business combination

 

The Company accounts for business combinations under the acquisition method of accounting in accordance with ASC 805. This method requires, among other things, that the fair value of the consideration transferred be allocated to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The excess of the fair value of the consideration transferred over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes estimates and assumptions, particularly with respect to intangible assets such as in-process research and development and the fair value of any equity issued as consideration. Management’s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. During the measurement period, not to exceed one year from the acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed, with a corresponding offset to goodwill, if new information is obtained about facts and circumstances that existed as of the acquisition date. Such adjustments may be material. After the measurement period, any subsequent adjustments are reflected in the unaudited condensed consolidated statements of operations. Acquisition-related costs, consisting primarily of third-party legal, accounting and valuation fees, are expensed as incurred.

 

In-process Research and Development Assets

 

In-process research and development (“IPR&D”) assets acquired in a business combination are recorded at fair value as of the acquisition date and are presented as “Intangible assets - IPR&D” on the unaudited condensed consolidated balance sheets. IPR&D assets are used in research and development activities and are classified as indefinite-lived intangible assets until the completion or abandonment of the associated research and development efforts. Accordingly, IPR&D assets are not amortized during the development period. Upon completion of the associated research and development efforts, the Company will determine the estimated useful life of the related technology and begin amortizing the carrying value of the asset over that period. If an IPR&D asset is abandoned, its carrying value is written off, and if it is determined to be impaired, its carrying value is written down to fair value; in either case, the Company records an impairment charge in the period in which the abandonment or impairment occurs. No impairment of IPR&D assets was recognized during the three and nine months ended September 30, 2026.

 

Goodwill

 

Goodwill represents the excess of the purchase price of an acquired business over the fair value of the identifiable net assets acquired. Goodwill is not amortized and is tested for impairment annually as of December 31, or more frequently if events or changes in circumstances indicate that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. The Company has one reporting unit. An impairment loss is recognized for the amount by which the carrying amount of the reporting unit exceeds its fair value, limited to the carrying amount of goodwill. No goodwill impairment was recognized during the three and nine months ended September 30, 2026.

 

Segment information

 

In accordance with ASC 280, Segment Reporting, the Company identifies its operating segments according to how the Company’s business activities are managed and evaluated. ASC 280 establishes standards for companies to report financial statement information about operating segments, products, services, geographic areas, and major customers. Operating segments are defined as components of an enterprise for which separate financial information is available that is regularly evaluated by the Company’s chief operating decision maker (“CODM”), or group, in deciding how to allocate resources and assess performance.

 

The CODM has been identified as the Chief Executive Officer, who reviews the operating results for the Company as a whole to make decisions about allocating resources and assessing financial performance. Accordingly, management has determined that the Company only has one operating and reportable segment.

 

14
 

 

When evaluating the Company’s performance and making key decisions regarding resource allocation the CODM reviews several key metrics, which include the following:

 

(in thousands)  2026   2025   2026   2025 
  

Three months ended September 30,

  

Nine months ended September 30,

 
(in thousands)  2026   2025   2026   2025 
                
General and administrative:                    
Legal fees  $77   $10   $162   $15 
Accounting and other professional fees   196    123    642    244 
Stock compensation expense   1,678    1,257    1,913    1,424 
Payroll and benefits   231    68    623    129 
Other   436    147    780    150 
Research and development:                    
Stock compensation expense   677    -    698    - 
Payroll and benefits   562    -    998    - 
Nanofabrication lab usage expense   357    -    699    - 
University expense   33    -    154    - 
Other   174    -    361    - 
Total operating expenses  $4,421   $1,605   $7,030   $1,962 

 

The key measures of segment profit or loss reviewed by our CODM are operating expenses. Operating costs are reviewed and monitored by the CODM to manage and forecast cash. The CODM also reviews operating costs to manage, maintain and enforce all contractual agreements to ensure costs are aligned with all agreements and budget.

 

Recently Issued Accounting Pronouncements

 

In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses. ASU 2024-03 requires additional disclosure of specific types of expenses included in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact that the adoption of ASU 2024-03 will have on its unaudited condensed consolidated financial statements and disclosures.

 

ASU 2025-12 Codification Improvements. In December 2025, the FASB issued this ASU which addresses 33 specific technical issues to clarify GAAP. The amendments in this update are effective for all entities for annual reporting periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted for all entities. The Company is currently evaluating the impact that the adoption of ASU 2025-12 will have on its unaudited condensed consolidated financial statements and disclosures.

 

The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company’s financial reporting, the Company undertakes a study to determine the consequence of the change to its unaudited condensed consolidated financial statements and assures that there are proper controls in place to ascertain that the Company’s financials properly reflect the change. Management does not believe that any recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying condensed consolidated financial statements.

 

Note 3. Business Combination

 

On July 31, 2026 (the “Closing Date”), the Company acquired 100% of the outstanding common stock of Vega Links Inc. (“Vega Links”), a Delaware corporation and developer of semiconductor integrated circuits for high-speed interconnects, pursuant to a Share Exchange Agreement and Plan of Reorganization (the “Share Exchange Agreement”) with Vega Links and its stockholders (the “Share Exchange”). The acquisition expands the Company’s optical interconnect platform with Vega Links’ high-speed interconnect integrated circuit and digital signal processing technology and adds Vega Links’ engineering team. The acquisition was accounted for as a business combination under ASC 805, with the Company as the acquirer. The results of Vega Links are included in the Company’s condensed consolidated financial statements from the Closing Date.

 

15
 

 

In the Share Exchange, each outstanding share of Vega Links common stock was exchanged for 0.4 of a share of the Company’s common stock, and the Company issued 4,472,000 shares of restricted common stock (the “Consideration Shares”) to the former Vega Links stockholders. The Consideration Shares had an aggregate fair value of $16.9 million, based on a fair value of $3.78 per share determined by an independent valuation as of the Closing Date. The Company’s quoted OTC price was not used because of infrequent, low-volume trading. The Consideration Shares remain subject to the service-based vesting conditions of each holder’s Vega Links stock purchase agreement, which the Company assumed, generally vesting over four years with a one-year cliff (one year monthly for certain consultants) from the holder’s original vesting start date, and are subject to repurchase by the Company at the holder’s original purchase price upon termination of service before vesting. Because continued post-combination service is required, the Consideration Shares are replacement share-based payment awards (the “Replacement Awards”). The portion of their fair value attributable to pre-combination service, $29 thousand, was included in consideration transferred. The remaining $16.9 million is attributable to post-combination service and is recognized as stock-based compensation expense (see Note 8), including $321 thousand recognized on the Closing Date for Consideration Shares that required no further service, which is included in general and administrative expense in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2026. No cash consideration was paid.

 

The following table summarizes the consideration transferred as of the Closing Date (in thousands):

 

      
Share consideration  $16,904 
Less: fair value of replacement awards attributable to post-combination service   (16,875)
Total consideration transferred  $29 

 

The following table summarizes the preliminary allocation of consideration transferred to the estimated fair values of the net assets acquired by the Company as of the acquisition date (in thousands):

 

      
Cash  $70 
Prepaid expenses and other current assets   3 
Laptops and IT equipment, net   3 
Intangible assets - IPR&D   21 
Goodwill   26 
Total assets   123 
Accounts payable   (9)
Loans from shareholders   (25)
Accrued liabilities   (1)
Liability for unvested restricted stock   (56)
Deferred tax liabilities   (3)
Total liabilities   (94)
Net assets acquired  $29 

 

The Company engaged a third-party valuation specialist to assist in determining the fair value of the Consideration Shares and the identifiable intangible asset acquired as of the acquisition date.

 

The fair value of the Consideration Shares was based on a fair value of the Company’s common stock of $3.78 per share. The Company utilized the guideline transaction method, a form of the market approach, to estimate the equity value of the combined company, and the option pricing method to allocate that value among its common stock, stock options and warrants. The significant assumptions used in the option pricing method included a term of 0.25 years, expected volatility of 81.0% based on guideline public companies, and a risk-free rate of 3.76%. No discount for lack of marketability was applied because the resale restrictions applicable to the Consideration Shares are specific to the holders rather than a characteristic of the Company’s common stock. The same fair value was used to measure the post-combination stock-based compensation for the Replacement Awards (see Note 8).

 

The Company utilized the replacement cost method, a form of the cost approach, to determine the fair value of the in-process research and development (“IPR&D”) asset, which represents Vega Links’ interconnect and digital signal processing technology under development. Because the technology does not yet generate revenue, this method estimates the cost a market participant would incur to recreate the technology. The fair value was calculated from management’s estimate of the costs to recreate the technology, with no adjustment for obsolescence, plus a developer’s profit margin of 13.0%, based on the margins of publicly traded outsourced software development companies, and an opportunity cost reflecting a rate of return of 50.0% over an average development lead time of approximately 0.26 years. IPR&D is an indefinite-lived intangible asset that is not amortized until the related project is completed or abandoned and is tested for impairment at least annually.

 

The deferred tax liability arises from the excess of the book basis of the IPR&D over its carryover tax basis, as the Share Exchange was structured as a reorganization under Section 368(a)(1)(B) of the Internal Revenue Code. The liability for unvested restricted stock represents purchase price deposits received by Vega Links from holders of unvested shares that are refundable if the shares are forfeited and is reclassified to additional paid-in capital as the related Consideration Shares vest.

 

Goodwill of $26 thousand is attributable primarily to Vega Links’ assembled engineering workforce and the expected synergies from integrating its technology with the Company’s platform. None of the goodwill is expected to be deductible for income tax purposes. All of the goodwill was assigned to the Company’s single reportable segment. In connection with the acquisition, the Company also recognized an income tax benefit of $1 thousand from a partial release of its valuation allowance, because the deferred tax liability recognized in acquisition accounting provides a source of future taxable income for the Company’s existing deferred tax assets.

 

16
 

 

The purchase price allocation is preliminary. The fair values of the IPR&D asset and the deferred tax liability, and the fair value of the Vega Links equity used to attribute the Consideration Shares between pre- and post-combination service, remain subject to change as the Company completes its valuation procedures. The Company will finalize the allocation as soon as practicable and no later than one year from the Closing Date.

 

The Company incurred $215 thousand of acquisition-related costs, consisting of legal, accounting and valuation fees, which were expensed as incurred and are included in general and administrative expense in the unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2026. In accordance with the Share Exchange Agreement, the Company bore the fees of Vega Links’ attorneys and accountants.

 

Vega Links had no revenue from the Closing Date through September 30, 2026, and its net loss included in the Company’s condensed consolidated statements of operations for that period was $3 thousand.

 

Unaudited Pro Forma Information

 

The following unaudited pro forma information presents the combined results of operations of the Company and Vega Links as if the acquisition had been completed on January 1, 2025 (in thousands):

 

    2026    2025    2026    2025 
  

Three months ended September 30,

  

Nine months ended September 30,

 
                 
    2026    2025    2026    2025 
                     
Revenue  $-   $-   $-   $- 
Net loss  $(3,570)  $(3,322)  $(8,304)  $(8,772)

 

The pro forma information reflects stock-based compensation on the Replacement Awards as if the post-combination service period had begun on January 1, 2025, and eliminates stock-based compensation recognized by Vega Links on its original awards prior to the acquisition. Acquisition-related costs of $215 thousand, stock-based compensation of $321 thousand for Consideration Shares requiring no post-combination service, and the income tax benefit of $1 thousand from the partial release of the Company’s valuation allowance are reflected in the nine months ended September 30, 2025, and are excluded from the three and nine months ended September 30, 2026. The pro forma information is not necessarily indicative of the results of operations that would have occurred had the acquisition been completed on January 1, 2025, or of future results of the combined company.

 

Note 4. Property and Equipment, Net

 

(in thousands)     September 30,   December 31, 
   Estimated Useful Life  2026   2025 
Laptops and IT equipment  3 years  $12   $      - 
Furniture and fixtures  7 years   22    - 
Lab equipment  5 years or less   325    - 
Construction in progress  —   1,051    - 
Property and equipment, gross      1,410    - 
Less: accumulated depreciation      (32)   - 
Property and equipment, net     $1,378   $- 

 

The Company recorded $17 thousand and $32 thousand of depreciation expense during the three and nine months ended September 30, 2026, respectively. For the nine months ended September 30, 2026, $1 thousand was included in general and administrative expense and the remainder in research and development expense in the unaudited condensed consolidated statements of operations. There were no fixed assets as of December 31, 2025.

 

17
 

 

Note 5. Accrued Expenses and Other Liabilities

 

(in thousands)  September 30,   December 31, 
   2026   2025 
         
University-related payable  $160   $175 
Professional fees   214    68 
Accrued payroll   15    23 
Other   21    15 
Total  $410   $281 

 

Note 6. Related Party Debt and Transactions

 

Related party consulting arrangements

 

Beginning in March 2025, the Company utilized consulting services provided by Dalton DenBaars, the son of Steven DenBaars, a founding member and director of the Company, on an as-needed basis. Effective October 15, 2025, Dalton DenBaars became a part-time employee and receives an annual salary of $90 thousand. There were no accrued payroll or accrued expenses related to Dalton as of September 30, 2026 and December 31, 2025. The Company expensed $23 thousand and $3 thousand in general and administrative expense related to compensation expense for Dalton during the three months ended September 30, 2026 and 2025, respectively. The Company expensed $74 thousand and $4 thousand in general and administrative expense related to compensation expense for Dalton during the nine months ended September 30, 2026 and 2025, respectively.

 

During the nine months ended September 30, 2026, the Company consulted Steven DenBaars on various services and as of September 30, 2026 and December 31, 2025, accounts payable included $11 thousand and $0, respectively, for unpaid amounts due to him. The Company expensed $32 thousand and $89 thousand in general and administrative expense related to compensation expense for Steven during the three and nine months ended September 30, 2026, respectively. There was no expense related to compensation expense for Steven during the three and nine months ended September 30, 2025.

 

Jeffrey Shealy, the Company’s President and Chief Executive Officer, incurs business expenses on behalf of the Company that are reimbursed through expense reports. As of September 30, 2026, accrued expenses and other liabilities included $11 thousand payable to Mr. Shealy for unreimbursed business expenses. During the three and nine months ended September 30, 2026, the Company recognized in general and administrative expense compensation expense for Mr. Shealy of $355 thousand and $505 thousand, respectively. During the three and nine months ended September 30, 2025, the Company recognized in general and administrative expense compensation expense for Mr. Shealy of $63 thousand and $115 thousand, respectively.

 

During 2025, the Company entered into a consulting agreement with Erica Honick, the spouse of Jeffrey Shealy, the Company’s President and Chief Executive Officer, pursuant to which Ms. Honick provides assistance in areas of human resources (inclusive of talent management and learning & development), as well as risk management and internal audit for the Company’s optical devices and related applications. Under this agreement, Ms. Honick is paid $10,000 per month beginning October 1, 2025. In addition, Ms. Honick was granted the right to purchase 30,000 shares of the Company’s common stock, which vest over a four-year period. During the three and nine months ended September 30, 2026, the Company recognized $30 thousand and $90 thousand of cash compensation in general and administrative expense related to services performed by Ms. Honick, respectively.

 

In July 2026, Ms. Honick was also granted performance-based options to purchase 20,000 shares of the Company’s common stock under the 2025 Plan at an exercise price of $4.86 per share. The options became eligible to vest upon the Company’s completion of the Vega Links acquisition on July 31, 2026, which satisfied the Acquisition Milestone, and vest monthly over the following twelve months. The Company recognized $19 thousand of stock-based compensation expense related to these options during the three and nine months ended September 30, 2026.

 

In January 2026, the Company purchased certain test equipment from James Shealy, the brother of Jeffrey Shealy, the Company’s President and Chief Executive Officer, for $28 thousand. On September 22, 2026, the Company’s board of directors (the “Board”) granted 15,000 restricted stock units to James Shealy under the 2025 Plan. The restricted stock units vest monthly over four years from April 26, 2026, subject to a one-year cliff.

 

During 2025, the Company entered into a consulting agreement with Maggie Nguyen LLC, pursuant to which Ms. Nguyen, the spouse of Richard Ogawa, a director of the Company, provides assistance in areas of finance, accounting, payroll, and benefits. Under this agreement, Maggie Nguyen LLC is paid $10,000 per month beginning October 1, 2025. In addition, Ms. Nguyen was granted the right to purchase 30,000 shares of the Company’s common stock, which vest over a four-year period. During the three and nine months ended September 30, 2026, the Company recognized $30 thousand and $90 thousand of cash compensation in general and administrative expense related to services performed by Ms. Nguyen, respectively. There was $10 thousand outstanding and included in accounts payable under this arrangement as of September 30, 2026.

 

18
 

 

In July 2026, Ms. Nguyen was also granted performance-based options to purchase 20,000 shares of the Company’s common stock under the 2025 Plan at an exercise price of $4.86 per share. The options became eligible to vest upon the Company’s completion of the Vega Links acquisition on July 31, 2026, which satisfied the Acquisition Milestone and vest monthly over the following twelve months. The Company recognized $19 thousand of stock-based compensation expense related to these options during the three and nine months ended September 30, 2026.

 

Richard Ogawa and Ms. Nguyen were stockholders of Vega Links and received 120,000 and 20,000 Consideration Shares, respectively, in the Share Exchange (see Note 3). As of September 30, 2026, 40,000 of Mr. Ogawa’s and 6,667 of Ms. Nguyen’s Consideration Shares remained unvested.

 

Karthik Gopalakrishnan, Vega Links’ former Chief Executive Officer, was appointed the Company’s Chief Technology Officer on the Closing Date and, as such, is a member of the Company’s management. He received 2,000,000 Consideration Shares in the Share Exchange (see Note 3), all of which remained unvested and subject to repurchase as of September 30, 2026. In February 2026, prior to the acquisition, Vega Links entered into a non-interest-bearing, unsecured loan agreement with Mr. Gopalakrishnan, due on demand, in the amount of $25 thousand, which the Company assumed in the Share Exchange and repaid in full on September 24, 2026. Prior to the Closing Date, Mr. Gopalakrishnan also paid $2 thousand of patent registration costs on behalf of Vega Links; the amount is reimbursable, non-interest-bearing and due on demand, and is included in accounts payable as of September 30, 2026.

 

Note 7. Commitments and Contingencies

 

Certain conditions may exist as at the date the unaudited condensed consolidated financial statements are issued, which may result in a loss to the Company, but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. As of the condensed consolidated balance sheet dates, there were no contingent liabilities to assess.

 

Litigation

 

Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recorded when it is probable that a liability has been incurred and the amount can be reasonably estimated. There are no matters currently outstanding.

 

Indemnification

 

In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners, and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with officers and members of the Board that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. As of September 30, 2026 and December 31, 2025, the Company had not experienced any losses related to these indemnification obligations, and no claims with respect thereto were outstanding.

 

Leases

 

The Company has two operating leases for office and laboratory space. The first lease was entered into on November 26, 2025 and commenced on January 1, 2026 with an initial term of 36 months. The second lease commenced on July 16, 2026, and expires on July 31, 2028, with no renewal options. At commencement of the second lease, the Company recognized a lease liability of $187 thousand and a ROU asset of $196 thousand. The leases are used for research and development purposes. The Company determines if a contract is or contains a lease based on its relevant terms in accordance with ASC 842, including whether it conveys to the Company the right to obtain substantially all the economic benefits of the identified leased asset and to direct its use.

 

19
 

 

The components of lease cost were as follows (in thousands; all recorded in research and development expense):

 

   Three Months Ended   Nine Months Ended 
   September 30, 2026   September 30, 2026 
         
Operating lease cost  $41   $78 
Total lease cost  $41   $78 

 

Other information related to leases is as follows (dollars in thousands):

  

   Nine Months Ended 
   September 30, 2026 
     
Operating cash flows from operating leases  $66 
Variable lease payments   50 
ROU assets obtained in exchange for new operating lease liabilities  $376 

 

   As of 
   September 30, 2026 
     
Weighted average remaining lease term (in years)   2.0 
Weighted average discount rate   9.7%

 

Future minimum payments under long-term leases at September 30, 2026 are as follows (in thousands):

 

Year Ending December 31,  (in thousands) 
     
2026 (three months remaining)  $45 
2027   182 
2028   141 
Total lease payments   368 
Less: imputed interest   (33)
Total lease liabilities  $335 

 

Note 8. Stockholders’ Equity

 

On April 20, 2026, the Company entered into subscription agreements (each a “Subscription Agreement”) with certain accredited investors and sold in an initial closing of a private placement (the “Offering”) an aggregate of 3,773,853 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for an aggregate purchase price of $15.1 million, at a purchase price of $4.00 per Share. A total of 374,761 warrants were issued in connection with the Offering.

 

On April 30, 2026, the Company and certain accredited investors mutually agreed to effect, and effected, an additional closing, with respect to 470,000 Shares for gross proceeds of $1.9 million. Total proceeds raised from this offering were $17.0 million.

 

20
 

 

In connection with the Offering, Laidlaw & Company (UK) Ltd. (the “Placement Agent”) was paid at each closing (i) a cash fee equal to ten percent (10%) of the gross proceeds delivered to the Company on a closing date by parties introduced by the Placement Agent and (ii) five percent (5%) of the gross proceeds delivered to the Company on a closing date by parties introduced by the Company, as well as a non-allocable expense reimbursement equal to two (2%) of the gross proceeds delivered by Placement Agent introduced investors on a closing date to the Company, and one (1%) of the gross proceeds delivered by Company introduced investors on a closing date to the Company. The Placement Agent also received, at the final closing of the private placement, warrants to purchase shares of Common Stock in an amount equal to ten percent (10%) of the Common Stock sold to Placement Agent introduced parties which are exercisable for five (5) years and have an exercise price equal to 120% of the lowest price per share of the shares of Common Stock issued or issuable to investors in the Offering. The Company agreed to pay certain other expenses of the Placement Agent, including the fees and expenses of its counsel, in connection with the Offering. Subject to certain customary exceptions, the Company also indemnified the Placement Agent to the fullest extent permitted by law against certain liabilities that may be incurred in connection with the Offering, including certain civil liabilities under the Securities Act of 1933, and, where such indemnification is not available, to contribute to the payments the Placement Agent and its sub-agents may be required to make in respect of such liabilities.

 

The Company received aggregate gross proceeds of $17.0 million from the Offering and additional closing, which were allocated between the common stock and the warrants. Direct and incremental issuance costs of $2.2 million, including placement agent fees and related offering expenses, were recorded as a reduction of additional paid-in capital, resulting in net proceeds of $14.8 million recorded within common stock and additional paid-in capital. The Company evaluated the warrants under ASC 480 and ASC 815 and determined that they meet the criteria for equity classification. Accordingly, the warrants are classified within stockholders’ equity.

 

Warrants

 

As of September 30, 2026, there were outstanding and exercisable warrants to purchase an aggregate of 9,141,055 shares of common stock at a weighted average exercise price of $1.66 per share. The warrants had a weighted average remaining contractual term of 1.35 years as of September 30, 2026.

 

Replacement Awards

 

In connection with the acquisition of Vega Links, the Company issued 4,472,000 Consideration Shares to the former Vega Links stockholders in exchange for their Vega Links common stock. The Company assumed each holder’s Vega Links stock purchase agreement, and the terms of the Consideration Shares are substantially similar to those of the original Vega Links awards. The Consideration Shares generally vest over four years with a one-year cliff (one year monthly for certain consultants) from the holder’s original vesting start date and are subject to repurchase by the Company at the holder’s original purchase price upon termination of service before vesting. Because continued post-combination service is required, the Consideration Shares are accounted for as replacement share-based payment awards. The total fair value of these Replacement Awards is $16.9 million, of which $29 thousand is attributable to service rendered through July 31, 2026, the acquisition Closing Date, and was included in consideration transferred. The fair value of the Replacement Awards of $16.9 million is attributable to post-combination service and is recognized as stock-based compensation expense over the remaining vesting period, including $321 thousand recognized on the Closing Date for Consideration Shares that required no further service. Refer to Note 3: Business Combination for the attribution of the Replacement Awards’ fair value between consideration transferred and post-combination compensation cost.

 

The Replacement Awards include repurchase rights that the Company assumed from Vega Links. If a holder’s service terminates, the Company may repurchase any issued but unvested Consideration Shares at the holder’s original purchase price. Purchase price deposits received for unvested shares are recorded as a liability for unvested shares. As the shares vest, the related liability is reclassified to common stock and additional paid-in capital; upon forfeiture, the deposit is refunded and the liability is extinguished. The liability is classified as current or noncurrent based on each award’s contractual vesting schedule. As of September 30, 2026, the Company had $18 thousand recorded in current liability for unvested shares and $38 thousand in noncurrent, related to 4,360,000 unvested shares of common stock subject to repurchase.

 

21
 

 

2025 Equity Incentive Plan

 

In 2025, the Company adopted the 2025 Equity Incentive Plan (the “2025 Plan”), reserving 15% of the outstanding Common Stock on a fully-diluted basis for the future issuance, at the discretion of our board of directors, of options and other incentive awards to officers, key employees, consultants and directors of the Company and its subsidiaries. The 2025 Plan includes a customary “evergreen” provision with respect to the annual increase of the number of shares at the beginning of each fiscal year of the Company of up to the lesser of (i) four percent (4.0%) of the shares of Common Stock outstanding on the last day of the immediately preceding fiscal year, commencing on the first day of the second fiscal year of the Company beginning after the final closing of the Offering or (ii) such number of shares as determined by the administrator. Repricing outstanding stock awards is not permitted without the approval of the Company’s stockholders, except for certain proportionate capitalization adjustments as set forth in the 2025 Plan. The 2025 Plan terminates on September 29, 2035.

 

The amount, terms of grants, and exercisability provisions are determined and set by the Company’s board of directors or compensation committee. The Company measures employee and nonemployee stock-based awards at grant-date fair value. For employee awards with service-based graded vesting, compensation expense is recognized on a straight-line basis over the requisite service period, subject to a floor equal to the grant-date fair value of the vested portion. For nonemployee awards with graded vesting, each separately vesting tranche is recognized from the service inception date to its vesting date.

 

The Company has issued service-based non-statutory stock options, service-based incentive stock options and performance-based stock options. The options generally have a contractual life of up to 10 years and may be exercisable in cash or as otherwise determined by the board of directors. Service-based options generally vest over a period of four years. Performance-based options vest upon achievement of the specified performance condition, followed by a service-vesting period. On July 11, 2026, the Board of Directors granted performance-based stock options to purchase 590,000 shares of the Company’s common stock under the 2025 Plan at an exercise price of $4.86 per share and a contractual term of ten years. The options become eligible to vest only upon the Company’s completion of a qualifying strategic acquisition by the end of calendar year 2026 (the “Acquisition Milestone”), followed by monthly vesting over the following twelve months. The Acquisition Milestone was achieved upon the completion of the Vega Links acquisition on July 31, 2026. These options are included in the stock option activity table below.

 

The following table summarizes the stock option activity (aggregate intrinsic value in thousands):

 

   Shares   Weighted-Average Exercise Price   Weighted-Average Remaining Contractual Term (Years)   Aggregate Intrinsic Value 
                 
Outstanding at December 31, 2025   -   $-           
Granted   1,820,000    2.63           
Outstanding at September 30, 2026   1,820,000   $2.63    9.5   $2,878 
Exercisable at September 30, 2026   365,833   $1.69    9.4   $822 

 

The aggregate intrinsic value of the outstanding options as of September 30, 2026 was approximately $2.9 million, and the aggregate intrinsic value of options vested and exercisable was approximately $0.8 million. Options granted during the nine months ended September 30, 2026 had a weighted-average grant-date fair value of $1.18. The fair value of options vested during the nine-month periods ended September 30, 2026 and 2025 amounted to $297 thousand and $0, respectively. There were no options exercised during the three- and nine-month periods ended September 30, 2026 and 2025.

 

The grant date fair value of each stock option granted during the nine months ended September 30, 2026 was estimated using the Black-Scholes option-pricing model using the following weighted-average assumptions:

 

   Nine Months Ended 
   September 30, 2026 
     
Expected volatility   60.6%
Expected dividends   0.0%
Expected term (in years)   5.4 
Risk-free rate   4.33%
Exercise price  $4.86 

 

22
 

 

Restricted Stock Awards

 

The fair value of the Consideration Shares of $3.78 per share was determined as of the July 31, 2026 acquisition date using the valuation methods and assumptions described in Note 3. The RSUs and PSUs granted during the nine months ended September 30, 2026 were measured using the same fair value of $3.78 per share.

 

The following table summarizes the award activity for the nine months ended September 30, 2026, including 4,472,000 Consideration Shares issued in the Vega Links acquisition (see Note 3):

 

   Shares  

Weighted Average

Grant Date Fair Value

 
         
Unvested at December 31, 2025   258,334   $1.14 
Granted   4,622,000    3.69 
Vested   (176,584)   2.81 
Forfeited   -    - 
Unvested at September 30, 2026   4,703,750   $3.59 

 

Restricted Stock Units

 

The Company’s restricted stock units vest over four years with a 1-year cliff. The following table summarizes the RSU activity during the nine months ended September 30, 2026.

 

   Shares  

Weighted Average

Grant Date Fair Value

 
         
Unvested at December 31, 2025   -   $- 
Granted   133,750    3.78 
Vested   -    - 
Forfeited   -    - 
Unvested at September 30, 2026   133,750   $3.78 

 

Performance-based restricted stock units

 

On September 22, 2026, the Board of Directors granted 1,600,000 performance-based restricted stock units (“PSUs”) under the 2025 Plan to certain officers, directors and employees of the Company. Each PSU represents the right to receive one share of the Company’s common stock on vesting. The following table summarizes restricted stock units contingent upon achievement of performance conditions, also known as PSUs, activity during the nine months ended September 30, 2026.

 

   Shares  

Weighted Average Grant

Date Fair Value

 
         
Unvested at December 31, 2025   -   $- 
Granted   1,600,000    3.78 
Vested   -    - 
Forfeited   -    - 
Unvested at September 30, 2026   1,600,000   $3.78 

 

For performance-based awards, including stock options and restricted stock units, (i) the fair value of the award is determined on the grant date and does not reflect the performance condition; (ii) the Company assesses the probability of achieving each performance condition associated with the award using reasonable assumptions based on the Company’s progress toward that condition, except that performance conditions tied to a liquidity event, such as a business combination or an up-listing of the Company’s common stock to a national securities exchange, are not considered probable until the event occurs; (iii) once a performance condition becomes probable of being met, the Company recognizes a cumulative adjustment for the portion of the award’s grant-date fair value attributable to service rendered from the service inception date, which is generally the grant date, and recognizes the remaining fair value over the remaining requisite service period; (iv) the Company reassesses the probability of achieving each performance condition at each reporting date; and (v) any change in estimate is accounted for through a cumulative adjustment in the period in which the change in estimate occurs. If a performance condition is not achieved, no compensation cost is recognized and any previously recognized cost is reversed. Awards with only service conditions are valued at fair value on the grant date, and the associated expense is recognized over the vesting period.

 

23
 

 

The Company recorded stock-based compensation expense (for its restricted awards, restricted stock units and stock options) in its accompanying unaudited condensed consolidated statements of operations as follows (in thousands):

 

   2026   2025   2026   2025 
   Three months ended September 30,   Nine months ended September 30, 
   2026   2025   2026   2025 
                 
Research and development  $677   $-   $698   $- 
General and administrative   1,678    1,257    1,913    1,424 
Total stock-based compensation expense  $2,355   $1,257   $2,611   $1,424 

 

As of September 30, 2026, total unrecognized compensation cost related to stock options, restricted stock awards, restricted stock units and the Consideration Shares was $17.4 million expected to be recognized over a weighted-average period of 3.4 years.

 

Note 9. Subsequent Events 

 

The Company has evaluated subsequent events from September 30, 2026 through November 13, 2026, the date these unaudited condensed consolidated financial statements were issued. Other than as described below, there were no subsequent events that required recognition or disclosure in these unaudited condensed consolidated financial statements.

 

Amendment to the 2025 Equity Incentive Plan

 

On November 5, 2026, at the Company’s 2026 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment to the 2025 Plan. The amendment provides that the number of shares of common stock reserved for issuance under the 2025 Plan will be, at all times, the greater of 10,000,000 shares or 15% of the Company’s issued and outstanding shares of common stock (on an as-converted basis) and clarifies that an increase in the share reserve pursuant to this provision does not require a further amendment to the 2025 Plan.

 

24
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

 

Forward-Looking Statements

 

Throughout this section, unless otherwise noted, “we,” “us,” “our,” “Company” and similar terms refer to Palomino Laboratories Inc. prior to the closing of the Merger, and to the Company after the closing of the Merger. Following is a discussion and analysis of our financial condition and results of operations. You should read the following together with our unaudited condensed consolidated financial statements and the related notes and other financial information included in this Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties as described under the heading “Forward-Looking Statements” elsewhere in this Report. You should review the disclosure under the heading “Risk Factors” in this Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

 

Basis of Presentation

 

The following discussion highlights our results of operations and the principal factors that have affected our financial condition as well as our liquidity and capital resources for the periods described and provides information that management believes is relevant for an assessment and understanding of the statements of consolidated financial condition and results of operations presented herein. The following discussion and analysis are based on our unaudited condensed consolidated financial statements contained in this Quarterly Report, which we have prepared in accordance with United States generally accepted accounting principles. You should read the discussion and analysis together with such unaudited condensed consolidated financial statements and the related notes thereto.

 

Overview

 

The Company is a fabless semiconductor company pioneering the next generation of high-performance microLED-based optoelectronic solutions for data communication. Our mission is to enable ultra-high-speed, energy-efficient optical interconnects that replace legacy copper-based PCIe and Ethernet links in compute-intensive environments. The Company is commercializing a breakthrough platform built on advanced gallium nitride (GaN) compound semiconductor materials. This proprietary technology enables scalable and cost-efficient manufacturing of ultra-compact, high-speed optical transceivers, with significant improvements in power, size, and bandwidth density over traditional laser-based solutions. Its differentiated value proposition lies in leveraging high-efficiency microLEDs as optical sources in transceiver modules that can be seamlessly integrated into silicon packages or interposers. This approach unlocks the potential for high-density, chip-scale optical I/O—fundamentally reshaping the future of data movement in AI servers, data centers and high-performance computing systems. See Note 1 to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report.

 

On September 29, 2025, Unite Acquisition 3 Corp.’s wholly owned subsidiary, Palomino Acquisition Co., a Delaware corporation formed in the State of Delaware on August 19, 2025 (“Merger Sub”), merged with and into Palomino Laboratories Inc., a privately held Delaware corporation (prior to the merger, “Private Palomino”). Pursuant to this transaction (the “Merger”), Private Palomino was renamed to Rhino Subsidiary Inc. and became the Company’s wholly owned subsidiary and all of the outstanding stock of Private Palomino was converted into shares of the Company’s common stock, par value $0.0001 per share. As a result, Unite ceased to be a shell company and continues as a public reporting company under the new name, Palomino Laboratories Inc.

 

The merger agreement contained customary representations and warranties and pre- and post-closing covenants of each party and customary closing conditions. The Company operates in a single reportable segment. All revenues, expenses, and assets are reflected on a consolidated basis. Accordingly, no additional segment disclosures are required under Accounting Standards Codification (ASC) 280, “Segment Reporting”.

 

The Merger was treated as a recapitalization and reverse acquisition for the Company for financial reporting purposes, and the Company is considered the acquirer for accounting purposes. As a result of the Merger and the change in the Company’s business and operations, a discussion of the past financial results of the Company is not pertinent, and under applicable accounting principles, the historical financial results of the Company, the accounting acquirer, prior to the Merger will be considered our historical financial results.

 

25
 

 

Since the Company’s inception in 2023, it has devoted substantially all of its efforts and financial resources to building the organization, including raising capital, organizing and staffing the company, business planning, and providing general and administrative support for these operations. Prior to the merger, the Company has funded its operations primarily with proceeds from the sale and issuance of simple agreements for future equity (“SAFEs”). From inception through September 30, 2026, the Company raised aggregate net proceeds of approximately $1.8 million from the issuance and sale of Simple Agreement for Future Equity (SAFE) Liabilities.

 

During the nine months ended September 30, 2026, the Company’s net losses were $7.0 million, and for the nine months ended September 30, 2025, the Company incurred a net loss of $2.4 million.

 

Based on the Company’s current operating plans, it estimates that its existing cash as of September 30, 2026 will be sufficient to support operations for at least one year from the issuance date of these condensed consolidated financial statements.

 

The Company expects to incur additional losses and negative cash flows for the foreseeable future as it continues to hire additional personnel, protect its intellectual property and grow its business. The Company may need to raise additional capital to support its continuing operations and pursue its long-term business plan. Financing activities may include, but are not limited to, public or private equity offerings, debt financing, or other sources. Such activities are subject to significant risks and uncertainties.

 

Uncertainty in the global economy presents significant risks to the Company’s business. The Company is subject to continuing risks and uncertainties in connection with the current macroeconomic environment, including increases in inflation, fluctuating interest rates, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics, recent bank failures, geopolitical factors, including the ongoing conflicts between Russia and Ukraine and in the Middle East and the responses thereto, and supply chain disruptions. While the Company is closely monitoring the impact of the current macroeconomic and geopolitical conditions on all aspects of the Company’s business, including the impacts on its employees, suppliers, vendors and business partners and the Company’s future access to capital, the ultimate extent of the impact on the Company’s business remains highly uncertain and will depend on future developments and factors that continue to evolve. Most of these developments and factors are outside the Company’s control and could exist for an extended period of time. The Company will continue to evaluate the nature and extent of the potential impacts to its business, results of operations, liquidity and capital resources.

 

Recent Developments

 

OTCQB Listing

 

On April 17, 2026, the Company’s common stock began trading on the OTCQB Venture Market under the symbol “PALX,” following approval of the Company’s listing application by OTC Markets Group Inc.

 

Private Placement

 

On April 20, 2026, the Company entered into subscription agreements (each a “Subscription Agreement”) with certain accredited investors and sold in an initial closing of a private placement (the “Offering”) an aggregate of 3,773,853 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”) for an aggregate purchase price of $15.1 million, at a purchase price of $4.00 per Share.

 

On April 30, 2026, the Company and certain accredited investors mutually agreed to effect, and effected, an additional closing, with respect to 470,000 Shares for gross proceeds of $1.9 million.

 

In connection with the Offering, Laidlaw & Company (UK) Ltd. (the “Placement Agent”) was paid at each closing (i) a cash fee equal to ten percent (10%) of the gross proceeds delivered to the Company on a closing date by parties introduced by the Placement Agent and (ii) five percent (5%) of the gross proceeds delivered to the Company on a closing date by parties introduced by the Company, as well as a non-allocable expense reimbursement equal to two (2%) of the gross proceeds delivered by Placement Agent introduced investors on a closing date to the Company, and one (1%) of the gross proceeds delivered by Company introduced investors on a closing date to the Company. The Placement Agent also received, at the final closing of the private placement, warrants to purchase shares of Common Stock in an amount equal to ten percent (10%) of the Common Stock sold to Placement Agent introduced parties which are exercisable for five (5) years and have an exercise price equal to 120% of the lowest price per share of the shares of Common Stock issued or issuable to investors in the Offering. The Company agreed to pay certain other expenses of the Placement Agent, including the fees and expenses of its counsel, in connection with the Offering. Subject to certain customary exceptions, the Company also indemnified the Placement Agent to the fullest extent permitted by law against certain liabilities that may be incurred in connection with the Offering, including certain civil liabilities under the Securities Act of 1933, and, where such indemnification is not available, to contribute to the payments the Placement Agent and its sub-agents may be required to make in respect of such liabilities.

 

26
 

 

Property and Equipment

 

During the nine months ended September 30, 2026, the Company purchased $1.4 million of property and equipment to support its laboratory operations, consisting primarily of laboratory equipment, of which $1.1 million was under construction and recorded as construction in progress as of September 30, 2026. Property and equipment, net was $1.4 million as of September 30, 2026, compared to none as of December 31, 2025 (see Note 4).

 

Stock Option Grants

 

On July 11, 2026, the Board of Directors approved grants of time-based and performance-based stock options under the Company’s 2025 Plan. The options have an exercise price of $4.86 per share, equal to the fair market value of the Company’s common stock at the grant date as determined by the Board, and a term of ten years. Time-based options covering 140,000 shares vest over four years, generally with a one-year cliff. Performance-based options covering 590,000 shares vest only upon the Company’s completion of a qualifying strategic acquisition by the end of calendar year 2026, followed by monthly service vesting over twelve months.

 

On July 31, 2026, the Company completed its acquisition of Vega Links Inc., which satisfied the Acquisition Milestone. Upon achievement of the milestone, the Company recognized cumulative compensation expense for the performance-based options for the service period from the July 11, 2026 grant date and is recognizing the remaining expense over the twelve-month service-vesting period that follows. Because the time-based and performance-based awards were granted during the three months ended September 30, 2026, and the Acquisition Milestone was achieved within that same period, stock-based compensation expense related to both awards is included in the Company’s unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2026.

 

Restricted Stock Unit Grants

 

On September 22, 2026, the Board of Directors granted 1,600,000 PSUs and 133,750 time-based RSUs under the 2025 Plan to certain officers, directors and employees of the Company, each with a grant-date fair value of $3.78 per unit. The time-based RSUs vest over four years, subject to a one-year cliff, from each holder’s vesting commencement date. The PSUs vest upon achievement of the specified performance conditions (see Note 8).

 

Vega Links Inc.

 

On July 31, 2026, following approval by the Board of Directors on July 30, 2026, the Company completed the acquisition of 100% of the outstanding common stock of Vega Links Inc. (“Vega Links”) pursuant to a Share Exchange Agreement and Plan of Reorganization, and issued 4,472,000 shares of restricted common stock to the former Vega Links stockholders. The acquisition was accounted for as a business combination under ASC 805, and the results of Vega Links are included in the Company’s unaudited condensed consolidated financial statements from the acquisition date. The purchase price allocation is preliminary. See Note 3, Business Combination, to the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report. In connection with the closing, Karthik Gopalakrishnan was appointed Chief Technology Officer and Rajesh Radhamohan was appointed Chief Product Officer of the Company.

 

New Lease

 

On July 14, 2026, the Board of Directors approved the execution of a lease for office and technical space in California. The lease was signed in July 2026. The lease commenced on July 16, 2026, and the related right-of-use asset and lease liability are included in the Company’s unaudited condensed consolidated balance sheet as of September 30, 2026.

 

Amendment to the 2025 Equity Incentive Plan

 

On November 5, 2026, at the Company’s 2026 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment to the 2025 Plan. The amendment provides that the number of shares of common stock reserved for issuance under the 2025 Plan will be, at all times, the greater of 10,000,000 shares or 15% of the Company’s issued and outstanding shares of common stock (on an as-converted basis) and clarifies that an increase in the share reserve pursuant to this provision does not require a further amendment to the 2025 Plan.

 

Operating Expenses

 

General and Administrative Expenses

 

General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance, and other administrative functions. Other significant costs include facilities related expenses, legal fees related to intellectual property and corporate matters, other professional fees for accounting and consulting services, and other administrative expenses.

 

The Company expects that its general and administrative expense will increase for the foreseeable future as it continues to support its operations to support the growth of its business. As a result of becoming a public reporting company through the Merger in September 2025, the Company has incurred, and expects to continue to incur increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums, board of director fees, investor relations costs and other expenses that it did not incur as a private company.

 

27
 

 

Research and Development Expenses

 

Research and development represent costs incurred to develop our technologies. These costs consist of employee and consultant costs, including salaries, employee benefit costs, stock-based compensation expenses, lease expenses, university contribution expense, nanofabrication lab usage expense as well as depreciation and amortization expense for capitalized assets associated with these functions. We expense all research and development costs in the periods in which they are incurred.

 

Other Income (Expense)

 

Change in fair value of SAFE notes

 

We assessed the SAFEs as liabilities under ASC 480. We carry the SAFEs at their estimated fair value at issuance and remeasure the estimated fair value through earnings until settled. The SAFEs were settled in connection with the Merger.

 

Interest Income

 

Interest income consists of interest earned from the Company’s cash and cash equivalents.

 

Income Tax Benefit

 

The Company has incurred net losses since inception and maintains a valuation allowance against its net deferred tax assets. Income tax benefit consists of changes in the valuation allowance resulting from deferred tax liabilities recognized in business combinations.

 

Results of Operations

 

The three months ended September 30, 2026, compared to the three months ended September 30, 2025

 

(in thousands)  Three Months Ended September 30,     
   2026   2025   $ Change 
             
Operating expenses:               
General and administrative  $2,618   $1,605   $1,013 
Research and development   1,803    -    1,803 
Total operating expenses   4,421    1,605    2,816 
Loss from operations   (4,421)   (1,605)   (2,816)
Other income (expense):               
Change in fair value of SAFE notes   -    (220)   220 
Interest income   -    -    - 
Total other income (expense)   -    (220)   220 
Income tax benefit   1    -    1 
Net loss  $(4,420)  $(1,825)  $(2,595)

 

General and Administrative Expenses

 

General and administrative expenses increased by $1.0 million to $2.6 million for the three months ended September 30, 2026, compared to $1.6 million for the three months ended September 30, 2025. The increase was primarily attributable to a $0.4 million increase in stock-based compensation expense, primarily related to the Replacement Awards issued in the acquisition of Vega Links, a $0.3 million increase in other general and administrative expenses (which includes $215 thousand of acquisition-related costs associated with the acquisition of Vega Links) and a $163 thousand increase in payroll and benefits costs. The remaining expense consisted of the increase in public company costs, legal fees, accounting and other professional fees.

 

28
 

 

Research and Development Expenses

 

Research and development expenses were $1.8 million for the three months ended September 30, 2026, compared to none for the three months ended September 30, 2025, reflecting the build-out of the Company’s research and development operations. Research and development expenses for the three months ended September 30, 2026 consisted primarily of $0.7 million of stock-based compensation expense, primarily related to the Replacement Awards issued in the acquisition of Vega Links. The remaining expenses consisted of payroll and benefits costs, nanofabrication lab usage expense, third-party consulting services, university-related research costs and other research and development costs.

 

Change in fair value of SAFE notes

 

We recognized a change in fair value of $0 related to the SAFE notes for the three months ended September 30, 2026 versus $220 thousand for the three months ended September 30, 2025. This change was mainly attributable to the Company’s SAFE notes that were in existence during 2025. Upon the Merger in September 2025, the SAFE notes were converted into common stock.

 

Income Tax Benefit

 

For the three months ended September 30, 2026, the Company recognized an income tax benefit of $1 thousand from a partial release of its valuation allowance in connection with the acquisition of Vega Links. No income tax benefit was recognized for the three months ended September 30, 2025.

 

The nine months ended September 30, 2026, compared to the nine months ended September 30, 2025

 

(in thousands)  Nine Months Ended September 30,     
   2026   2025   $ Change 
             
Operating expenses:               
General and administrative  $4,120   $1,962   $2,158 
Research and development   2,910    -    2,910 
Total operating expenses   7,030    1,962    5,068 
Loss from operations   (7,030)   (1,962)   (5,068)
Other income (expense):               
Change in fair value of SAFE notes   -    (461)   461 
Interest income   1    1    - 
Total other income (expense)   1    (460)   461 
Income tax benefit   1    -    1 
Net loss  $(7,028)  $(2,422)  $(4,606)

 

General and Administrative Expenses

 

General and administrative expenses increased by $2.2 million to $4.1 million for the nine months ended September 30, 2026, compared to $2.0 million for the nine months ended September 30, 2025. The increase was primarily due to increase in public company costs, professional fees, including $215 thousand of acquisition-related costs associated with the acquisition of Vega Links, $0.5 million increase in payroll and benefits costs. Share-based compensation expense also increased by $0.5 million, primarily related to the Replacement Awards issued in the acquisition of Vega Links.

 

29
 

 

Research and Development Expenses

 

Research and development expenses were $2.9 million for the nine months ended September 30, 2026, compared to none for the nine months ended September 30, 2025, reflecting the build-out of the Company’s research and development operations. Research and development expenses for the nine months ended September 30, 2026 consisted primarily of $1.0 million of payroll and benefits costs, $0.7 million of nanofabrication lab usage expense and $0.7 million of stock-based compensation expense, primarily related to the Replacement Awards issued in the acquisition of Vega Links. The remaining expenses consisted of third-party consulting services, university-related research costs and other research and development costs.

 

Change in fair value of SAFE notes

 

We recognized a change in fair value of $0 related to the SAFE notes for the nine months ended September 30, 2026 versus $461 thousand for the nine months ended September 30, 2025. This $461 thousand change was mainly attributable to the Company’s SAFE notes that were in existence during 2025. Upon the Merger in September 2025, the SAFE notes were converted into common stock.

 

Interest Income

 

For the nine months ended September 30, 2026 and 2025, the Company recognized $1 thousand of interest income in each period related to certain cash and cash equivalents.

 

Income Tax Benefit

 

For the nine months ended September 30, 2026, the Company recognized an income tax benefit of $1 thousand from a partial release of its valuation allowance in connection with the acquisition of Vega Links. No income tax benefit was recognized for the nine months ended September 30, 2025.

 

LIQUIDITY AND CAPITAL RESOURCES

 

Source of Liquidity

 

The Company has incurred net losses and negative cash flows from operations since its inception. Through September 30, 2026, the Company has primarily funded its operations through the sale and issuance of SAFE notes, common stock and warrants. The Company’s current capital resources, consisting of cash and cash equivalents are expected to be sufficient to fund operations for at least the next twelve months from the issuance date of its condensed consolidated financial statements. Company’s future viability depends on its ability to generate cash from operating activities or to obtain additional capital to finance its operations. There can be no assurance that Company will be able to secure sufficient funding on acceptable terms, or at all, to continue its operations.

 

Cash flows for the nine months ended September 30, 2026 and 2025

 

(in thousands)  Nine Months Ended September 30, 
   2026   2025 
         
Net cash used in operating activities  $(3,811)  $(391)
Net cash used in investing activities   (1,318)   - 
Net cash provided by financing activities   14,796    8,153 
Net increase in cash and cash equivalents  $9,667   $7,762 

 

Operating Activities

 

Net cash used in operating activities was $3.8 million for the nine months ended September 30, 2026. Cash used in operating activities reflected the Company’s net loss of $7.0 million, which was partially offset by net noncash charges of $2.6 million, primarily stock-based compensation of $2.6 million and depreciation of $32 thousand, and by changes in operating assets and liabilities of $575 thousand.

 

30
 

 

Net cash used in operating activities was $391 thousand for the nine months ended September 30, 2025. Cash used in operating activities reflected the Company’s net loss of $2.4 million which was offset by non-cash charges of $461 thousand related to the change in fair value of SAFE notes, $1.4 million of stock-based compensation and changes in operating assets and liabilities of $146 thousand.

 

Investing Activities

 

Net cash used in investing activities was $1.3 million for the nine months ended September 30, 2026, primarily due to purchases of property and equipment of $1.4 million, partially offset by $70 thousand of cash acquired in the acquisition of Vega Links. There were no investing activities for the nine months ended September 30, 2025.

 

Financing Activities

 

Net cash provided by financing activities was $14.8 million for the nine months ended September 30, 2026, primarily due to net proceeds of $14.8 million from the sale of common stock and warrants in the private placement, partially offset by the $25 thousand repayment of shareholder loans assumed in the acquisition of Vega Links.

 

Net cash provided by financing activities was $8.2 million for the nine months ended September 30, 2025, consisting of $1.7 million of proceeds from SAFE notes and $6.5 million of net proceeds from the issuance of common stock and warrants, after payment of $1.6 million of issuance costs.

 

Contractual Obligations and Commitments

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

Critical Accounting Policies and Significant Judgements and Estimates

 

Management’s discussion and analysis of Company’s financial condition and results of operations is based on its financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States of America. The preparation of these financial statements requires Company to make estimates and judgments that affect the reported amounts of assets and liabilities, and the disclosure of contingent assets and liabilities in its financial statements, as well as the reported expenses incurred during the reporting periods. Company bases its estimates on historical experience and on various other factors that Company’s management believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material.

 

While Company’s significant accounting policies are described in more detail in Note 2 to its financial statements included elsewhere in this document, Company believes that the accounting policies discussed below are critical to understanding its historical and future performance, as these policies relate to the more significant areas that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on its financial condition or results of operations.

 

Share-based compensation

 

The Company measures equity classified share-based awards granted to employees, non-employees and directors based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is the vesting period of the respective award. The Company accounts for forfeitures as they occur. For share-based awards with service-based vesting conditions, the Company recognizes compensation expense on a straight-line basis over the service period. Compensation cost for awards granted to non-employees is recognized as if the Company had paid cash for the services; for non-employee awards with graded vesting, each separately vesting tranche is treated as a separate award and is recognized from the service inception date to its vesting date. For awards with performance conditions, compensation cost is recognized when it is probable that the performance conditions will be achieved. The Company classifies share-based compensation expense in its unaudited condensed consolidated statements of operations in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Fair value is determined using a combination of the probability weighted expected return method and option pricing model. The Company’s share-based awards consist of restricted stock awards, including the Replacement Awards issued in the acquisition of Vega Links, restricted stock units, performance-based restricted stock units and stock options. The fair value of RSAs is measured based on the grant-date fair value of the restricted stock awards.

 

31
 

 

Stock options fair value is measured using the Black Scholes model and the model consists of the following inputs: the expected term of the stock options is estimated using the “simplified method” as the Company does not have sufficient historical information from which to develop reasonable expectations about future exercise patterns and post-vesting employment termination behavior for its stock option grants. The simplified method is the midpoint between the vesting period and the contractual term of the option. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The risk-free rate is based on the U.S. Treasury yield curve commensurate with the expected term of the option. The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay a dividend on its common stock.

 

Estimating the fair value of share-based award requires the input of subjective assumptions, including the estimated fair value of the Company’s common stock. The assumptions used in estimating the fair value of share-based awards represent management’s estimate and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

 

Business Combinations

 

The Company accounts for business combinations using the acquisition method, which requires the consideration transferred to be allocated to the assets acquired and liabilities assumed based on their estimated fair values at the acquisition date. In the acquisition of Vega Links, the most significant estimates were the fair value of the acquired IPR&D, which was valued using a replacement cost method, and the attribution of the fair value of the Replacement Awards between pre-combination service, included in consideration transferred, and post-combination service, recognized as stock-based compensation. The attribution depends on the fair value of Vega Links’ equity at the Closing Date, the grant dates of the original Vega Links awards and their vesting terms. Changes in these estimates during the measurement period could change the amounts allocated to goodwill and the stock-based compensation recognized in future periods.

 

Recent Accounting Pronouncements

 

See Note 2 to Company’s unaudited condensed consolidated financial statements found elsewhere in this document for a description of recent accounting pronouncements applicable to its financial statements.

 

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements as of September 30, 2026.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

The Company is a smaller reporting company and is not required to provide this information.

 

ITEM 4. CONTROLS AND PROCEDURES.

 

Disclosure Controls and Procedures

 

Our disclosure controls and procedures are designed to ensure that the information we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management to allow timely decisions regarding required disclosure.

 

32
 

 

Our management, with the participation and supervision of our Chief Executive Officer and our Chief Accounting Officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on such evaluation, our Chief Executive Officer and Chief Accounting Officer have concluded that as of such date, our disclosure controls and procedures were not, in design and operation, effective at a reasonable assurance level due to the material weaknesses in internal control over financial reporting described as follows. Because of our limited operations, we have a limited number of employees which prohibits a segregation of duties. In addition, we lack a formal audit committee with a financial expert. As we grow and expand our operations, we will engage additional employees and experts as needed. However, there can be no assurance that our operations will expand.

 

Changes in Internal Controls Over Financial Reporting

 

On July 31, 2026, the Company completed the acquisition of Vega Links. The Company is in the process of integrating Vega Links into its internal control over financial reporting. Other than the integration of Vega Links, there were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended September 30, 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Inherent Limitations on the Effectiveness of Controls

 

The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, in designing and evaluating the disclosure controls and procedures, management recognizes that any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable, not absolute assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business but cannot assure you that such improvements will be sufficient to provide us with effective internal control over financial reporting.

 

33
 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS.

 

We know of no active or pending legal proceedings against us, nor are we involved as a plaintiff in any proceedings or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any beneficial shareholder are an adverse party or has a material interest adverse to us.

 

ITEM 1A. RISK FACTORS.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

 

On April 20, 2026, the Company entered into subscription agreements with certain accredited investors and sold in an initial closing of a private placement (the “Offering”) an aggregate of 3,773,853 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share for an aggregate purchase price of $15.1 million, at a purchase price of $4.00 per Share.

 

On April 30, 2026, the Company and certain accredited investors mutually agreed to effect, and effected, an additional closing, with respect to 470,000 Shares for gross proceeds of $1.9 million.

 

On July 31, 2026, in connection with the acquisition of Vega Links, the Company issued 4,472,000 shares of restricted common stock to the former stockholders of Vega Links in exchange for all of the outstanding shares of Vega Links common stock (see Note 3 to the unaudited condensed consolidated financial statements). The shares were issued without registration under the Securities Act in reliance on the exemption provided by Section 4(a)(2) of the Securities Act as a transaction not involving a public offering.

 

On November 5, 2026, at the Company’s 2026 Annual Meeting of Stockholders, the Company’s stockholders approved an amendment to the 2025 Plan. The amendment provides that the number of shares of common stock reserved for issuance under the 2025 Plan will be, at all times, the greater of 10,000,000 shares or 15% of the Company’s issued and outstanding shares of common stock (on an as-converted basis) and clarifies that an increase in the share reserve pursuant to this provision does not require a further amendment to the 2025 Plan.

 

The Offering and sale of the Shares will be issued without registration under the Securities Act, in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) as a transaction not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. 

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES.

 

Not applicable.

 

ITEM 5. OTHER INFORMATION.

 

None.

 

ITEM 6. EXHIBITS.

 

Exhibit

Number

 
Description
10.1   Amendment to 2025 Equity Incentive Plan adopted on November 5, 2026 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on November 6, 2026)
     
31.1*   Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
31.2*   Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act
     
32.1*   Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
32.2*   Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

 

* Filed or furnished herewith.

 

34
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  PALOMINO LABORATORIES INC.
     
Date: November 13, 2026 By: /s/ Jeffrey Shealy
  Name: Jeffrey Shealy
  Title: President, Chief Executive Officer
    (Principal Executive Officer)
     
Date: November 13, 2026 By: /s/ Jason Tu
  Name: Jason Tu
  Title: Chief Accounting Officer
    (Principal Financial and Accounting Officer)

 

35

Keep reading